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Nonalcoholic fatty liver disease (NAFLD) is an “umbrella” term for the broad spectrum of 
the disease that begins from the simple steatosis to more progressive stages of 
nonalcoholic steatohepatitis (NASH), that includes hepatocellular ballooning, 
inflammation, and fibrosis. NAFLD is a growing epidemic globally, with 25% of the 
population predicted to be diagnosed with this disease. Liver biopsy is the only definitive 
method of diagnosis, despite the widespread use of sonography and elastography to 
predict the disease state. There is no current FDA approved medication for NAFLD/NASH. 
This is partly due to the lack of translatable disease model to predict the whole spectrum 
of the disease in humans as well as lack of definitive biomarker to predict the disease 
state. The goal of this dissertation is (1) To build an in vitro model for NAFLD to study the 
influence of fat over-load on xenobiotic as well as lipid metabolizing proteins (2) To use 
the model to help identify novel biomarkers in liver tissue to characterize the early stages 
of disease.  
Manuscript I: In recent times, there are numerous invitro models relevant to humans 
developed to predict the disease state. They involve monoculture, coculture and as well 
as multicellular culture in both 2D and 3D models to best represent the physiology and 
working of liver in the disease state. In this review, we have explored all the existing in 
vitro models of NAFLD relevant to humans as well as highlight the technological gaps in 
the current in vitro models for future development.  
Manuscript II: Human hepatic carcinoma cell lines are commonly used in in vitro studies 
of lipid and xenobiotic metabolism, as well as glucose regulation in normal and disease 
state. However, their validity is still under debate due to the variable expression of proteins 
in the cell lines and human hepatocytes. In this present study, we used a data independent 




the different cell lines versus (vs.) cryopreserved human hepatocytes (cHH) and human 
liver tissue (HLT). For this purpose, the global proteome from the whole cell homogenates 
of HepaRG, HepG2, Huh7 cell lines were compared to cHH and HLT. The MS2 spectra 
for all detectable peptides were quantified using Spectronaut™. In summary, 2715, 2578, 
2874, 2717 and 3083 proteins in, HepaRG, HepG2, Huh7, cHH and HLT, were identified 
at 1% FDR, respectively. The global proteome of the cHH significantly differed from the 
cancer hepatic cell lines. Within the cell lines, the global as well as ADME protein profile 
of HepaRG most closely correlated with cHH, with 84 out of 101 ADME proteins, identified 
in HepaRG cells. Within gluconeogenesis and glycolysis pathway, Huh7 cell line 
expressed proteins in high abundance in contrast to the other groups. Therefore, we show 
that the comparison demonstrates the capability of untargeted global proteomics to detect 
the differences in protein expression among the different groups. In addition, this study 
provides a comprehensive database of information to aid study design and model 
selection. 
Manuscript III: To manage NAFLD and related co-morbidities, patients are administered 
with an array of pharmacological agents.  Therefore, understanding of the effect of NAFLD 
on drug disposition is warranted.  Using a HepaRG model, we aimed to mimic steatosis in 
vitro, and to examine its effects on drug-metabolizing enzymes (DME) and transporters. 
HepaRG cells, differentiated in-house, were exposed to a mixture of saturated and 
unsaturated fatty acids (1:2 ratio of 0.5 mM palmitate and oleate complex conjugated to 
BSA for 72h) and were subjected to RNA sequencing and proteomic analyses.  Lipid 
accumulation was ascertained by Oil Red O (ORO) staining and triglyceride (TG) 
quantitation and cell viability by WST-1 determination. The treatment condition resulted in 
~6-fold increase in TG concentration without reducing cell viability.  RNA sequencing of 




(89 up- and 304 down-regulated).  Moreover, lipid loading resulted in significant down-
regulation of mRNA transcripts of transcription factors, NR1I2 (-1.18) and HNF4α (-0.55), 
phase 1 DMEs including CYP1A2 (-3.25), 2B6 (-2.02), 2C8 (-1.48), 2C9 (-2.00),2C19 (-
1.32) and 3A4 (-1.87), phase 2 DMEs including UGT1A6 (-0.36) and 2B7 (-1.09), 
SULT2A1 (-0.75) and 1E1 (-1.41) as well as clinically relevant transporters such as 
ABCC11 (-1.36), ABCG5 (-1.66), SLC10A1(-1.63) and SLCO2B1(-1.49). However, the 
protein expression did not show a significant change.  Furthermore, lipid loaded cells 
significantly upregulated AKR1B10 mRNA (2.17) and protein (0.99) that may regulate lipid 
as well as xenobiotic metabolism.  
Manuscript IV: Non-alcoholic fatty liver disease (NAFLD) is a global epidemic, present in 
over 10% of the world population, despite the majority of the population being 
undiagnosed. Liver biopsies are the only gold standard available for the confirmation of 
disease state. Other non-invasive diagnostics such as ultrasound and MRI are either 
inaccurate or expensive for routine use. Many markers for disease state are available that 
detect the onset of inflammation and fibrosis from moderate-to-high accuracy. However, 
there is a huge gap in specific biomarkers that can distinguish the NAFLD liver tissue from 
normal in early stages of the disease. Using SWATH-MS based Data-independent 
acquisition (DIA) strategy the dysregulated proteins in the in vitro model of hepatic 
steatosis was compared with human liver tissue (n=116) showing progressive stages of 
NAFLD. More than 2,500 proteins were identified in HepaRG and human hepatocyte 
model as well as human liver tissue.  Within the hepatocyte model, 40 proteins were 
dysregulated in steatosis. These proteins were screened in liver tissue and 6 common 
proteins were identified. The sensitivity and selectivity of the markers were analyzed using 




H2AFY (0.80), SNX1 (0.67), GCHFR (0.69), APO (0.69) and all the above markers 
showed significance P <0.05. 
Conclusion. This work demonstrates that in vitro human relevant disease model has the 
potential to explain the effect of NAFLD. Subsequently, the in vitro models when used in 
conjunction with human liver tissue aid in identification of novel biomarkers that may have 
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JUSTIFICATION OF RESEARCH 
1. NAFLD Background 
Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent disease in the United States 
as well as other parts of the world (Bellentani, 2017). A high-fat diet and lack of exercise 
can lead to the accumulation of free fatty acids and tri-acyl glycerides (TAG) in 
hepatocytes leading to the development of steatosis (Veteläinen et al., 2007; Koo, 2013). 
Excess free fatty acids (FA) derived from diet or inflammation-induced lipolysis in 
adipocytes results in the accumulation of TAGs in the form of lipid droplets (LDs) within 
the hepatocytes.  The occurrence of such LDs greater than 5% of hepatocytes is the 
diagnostic measure for the onset of NAFLD and liver biopsy is the only form of conclusive 
testing (Gan, Chitturi and Farrell, 2011; Gorden et al., 2015). The liver steatosis is often 
termed as the “first-hit” in the progression of NAFLD.  The “second-hit” is manifested via 
the reactive oxygen species (ROS) induced stress leading to the infiltration of 
inflammatory factors, hepatocellular ballooning and deposition of collagen fibers in 
hepatocytes as observed in NASH and fibrosis (Caldwell and Argo, 2010). About 29% of 
the patients diagnosed with NASH develop cirrhosis (Cohen, Horton and Hobbs, 2011). 
Current treatment involves lifestyle management, which in most cases is proven 
ineffective.  Hence, our long-term goal is to identify non-invasive and conclusive diagnostic 
methods for the identification of NAFLD as well as to discover a panel of biomarkers that 
could be potential therapeutic targets for the pharmacotherapy of NAFLD. 
 
2. Importance of studying the disease state with in-vitro systems 
To study steatosis, it is crucial to identify the appropriate disease model.  Nutrition and 
energy uptake are the critical determinants for the onset of NAFLD; however, significant 




mouse models fail to recapitulate the spectrum of NAFLD as seen in humans (Gómez-
Lechón, Jover and Donato, 2009; Merrell and Cherrington, 2011).  With a high-fat diet 
(HFD) simple steatosis is established; however, male C57BL/6 mice fail to progress to 
NASH even in the presence of high fructose-rich diet (Takahashi, Soejima and Fukusato, 
2012).  To establish NASH, most animal models are fed with methionine-choline-deficient 
(MCD) diet that results in NASH without inducing obesity.  Recent reports, suggest the 
development of liver steatosis and fibrosis with high fructose (HF) rich diet (Cydylo, Davis 
and Kavanagh, 2017). In addition, there are several genetically modified mouse models 
such as, ob/ob, db/db that contain mutations in the leptin gene; however, they too fail to 
recapitulate the full spectrum of the disease (Larter and Yeh, 2008).  This physiological 
mismatch makes it challenging to solely rely upon animal models for investigation of 
NAFLD. 
The use of primary human hepatocytes (PHH) or cryopreserved hepatocytes is considered 
the gold standard for in-vitro studies (Lecluyse and Alexandre, 2010). However, the 
availability of early-stage biopsy samples, limited time in culture before the onset of 
dedifferentiation renders the utility of PHH as an ineffective tool for model development. 
HepaRG cells are a human hepatocellular carcinoma cell line composed of a mixture of 
both hepatocyte-like and biliary-like cells.  They retain hepatic functions, expression of 
liver-specific genes and drug metabolism capacity at levels comparable to that of PHH 
(Guillouzo et al., 2007). Furthermore, they preserve their phenotype for over 2 weeks upon 
differentiation (Aninat et al., 2006).  This provides for a good window for model 
development and treatment modification. 




Omics technology is a broad term to denote the global detection of genes (genomics), 
mRNA (transcriptomics), protein (proteomics) and metabolites (metabolomics). The total 
mRNA in a cell or an organism provide a template for the translation of the expressed 
protein. The transcriptome can be analyzed using RNA sequencing method to provide an 
unbiased read-out of the all the expressed transcripts, the copy number of the individual 
transcripts as well as the presence alternatively spliced transcripts between disease and 
healthy state. This method of untargeted approach aids in the identification of novel genes 
that are over/under-expressed in disease state and embody a huge potential towards 
biomarker identification. 
Additionally, shotgun or bottom-up proteomic approach is emerging as a powerful tool for 
analyzing proteolytic peptides of high intensity eluting at the same time in a chromatogram 
chosen for fragmentation and quantification. The results generated are high throughput 
and have a complete proteome coverage that out-weighs the traditional labor and 
resource intensive western blotting techniques (Vildhede et al., 2015; Wiśniewski et al., 
2016). Data-dependent acquisition (DDA) methodology has been used more commonly in 
untargeted analysis (Gu et al., 2018). However, bias associated with the abundant 
peptides and the lack of sensitivity to quantify low-abundance proteins rendering limitation 
towards the analysis of individual protein of interest that are present in low expression(Shi 
et al., 2018). Hence, sequential window acquisition of all theoretical mass spectra 
(SWATH) analysis (AB Sciex, Concord, Canada) that follows a Data Independent 
Acquisition (DIA) methodology is used to compare the relative expression pattern among 
the groups (Huang et al., 2015; Gillet et al., 2012; Gao et al., 2017). This approach is 
sensitive to capture the low abundant proteins which makes it a unique and reliable tool 




Despite the unbiased, hypothesis generating potential observed in transcriptomics and 
proteomics methods, there exists a high probability for false positive results.  However, 
high confidence exists when these results from different approach and systems are 
analyzed together, and similar patterns emerge despite the method of detection. To date, 
we do not have a unique panel of the biomarkers or a non-invasive method for conclusive 





   
  




Grow HepaRG cells to 
confluence in 24 well plate for 
14 days
Differentiate HepaRG cells in
presence of 2% DMSO in 24 well
plate for 14 days
Replace with media enriched with fatty acids 
(oleic:palmitic acid, 2:1) for 24, 48 and 72 hrs.
Wash cells with 1X PBS. Add insulin (0.5, 
1, 2,10, 50, 100 uM) for 10 min to assess 
insulin response and measure pAKT/total 
AKT. Measure other surrogate markers 
such as triglycerides, cholesterol using 
calorimetric assay.
Proliferate HepaRG cells in 
25cm2 flask for 14 days
Measure the mRNA expression 
levels of whole genome with 
RNA-seq. 
Measure the protein levels with 
SWATH analysis. Enzyme activity 
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Nonalcoholic fatty liver disease (NAFLD) is an “umbrella” term for the broad 
spectrum of the disease that begins from the simple steatosis to more progressive stages 
of nonalcoholic steatohepatitis (NASH), that includes hepatocellular ballooning, 
inflammation, and fibrosis. NAFLD is a growing epidemic globally, with 25% of the 
population predicted to be diagnosed with this disease. Liver biopsy is the only definitive 
method of diagnosis, despite the widespread use of sonography and elastography to 
predict the disease state. There is no current FDA approved medication for NAFLD/NASH, 
due to the lack of definitive biomarker to predict the disease state or translatable disease 
and/or model to predict the whole spectrum of the disease in humans. In this review, we 
have explored all the existing in vitro models of NAFLD relevant to humans as well as 
highlight the technological gaps in the current in vitro models for future development.  
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Hepatic steatosis is characterized by the accumulation of lipids (> 5% of the 
hepatocytes) in the cytoplasmic region as micro and macrovesicular vacuoles. This may 
progress to nonalcoholic steatohepatitis (NASH), which results in hepatocellular injury (1). 
Steatosis is often reversible and self-limiting. However, ∼25% of the cases progress to 
NASH, wherein the liver may become fibrotic resulting in permanent damage. In terms of 
the worldwide incidence, it is noted that extreme variations occur in the reported range 
between the studies (2). The current estimates around the incidence of nonalcoholic fatty 
liver (NAFLD), ranges between 20-30% in Western countries and 5-18% in Asia, 
suggesting it to become the leading cause of end-stage liver disease and transplantation, 
in the next decade (3). The fluctuations in the estimates, is in part, associated with the 
lack of definitive biomarkers to characterize the disease state as well as the limitations in 
current testing methods. Due to these challenges, there are currently no US Food and 
Drug Administration (FDA)-approved medication to treat NAFLD or NASH (4, 5). 
Numerous risk factors have accentuated the development of NAFLD, namely, diet, 
lifestyle, age, gender, ethnicity, genetics, and metabolic disorders that impact the lipid 
metabolism and insulin resistance (Fig. 1.1) (2). Other risk factors involve, drug-induced 
toxicity, as seen in tetracycline and amiodarone, and environmental pollutants, such as 
bisphenol a (BPA), that may induce and ameliorate NAFLD (6, 7). Besides, the metabolic 
deregulation observed in the disease state may also impact the disposition and dosing of 
other concomitant medication within the patient population.  
To investigate the drug deposition of the administered drugs due to changes in 
hepatic metabolism in disease state as well as inspect the chemical-induced toxicity that 
ameliorates NAFLD; early-stage screening tools that most represent the disease state in 




for examining various molecular entities against therapeutic targets that contribute to 
disease progression, e.g., FXR agonists (8). Due to the widely acknowledged ethical and 
financial requirements that limit the animal use in exploratory studies (9), system-oriented 
approaches involving integrated into in vitro and in silico models to best predict the 
changes in human liver physiology, are emerging as valuable tools to study the molecular 
changes involved in the disease state (10). 
 In the forthcoming sections, we will provide context for the pathology of NAFLD, 
risk factors associated with the disease progression as well as the current sophisticated 
in-vitro human models that reflect the different stages underlying the etiology of NAFLD. 
The aim of this review is to provide comprehensive information on the existing in vitro 
models of NAFLD to aid the choice of appropriate model as well as highlight the 
technological gaps in the current in vitro models for future development.  
2. Pathology and Risk factors 
 
Lipid accumulation in the hepatocytes is the starting point for hepatic steatosis. 
However, with the severity of progression, the affected parenchyma is subdivided into 
three categories: 5%-33%, 34%-66%, and > 66% as mild, moderate, and severe, 
respectively (11). The occurrence of steatosis is spatially heterogenous in the liver, with 
lipids localized to zone 3 in the early stages of disease in contrast to panacinar localization, 
as seen with the progression of steatosis (12). This heterogeneity may lead to occasional 
overestimation of the degree of steatosis by histopathologists. In addition, conventional 
imaging (ultrasound, magnetic resonance imaging, or computed tomography), lack the 
sensitivity to detect hepatic steatosis less than 30% (13). However, newer technologies 
involving magnetic resonance imaging-estimated proton density fat fraction, and 1H-




Steatosis often triggers the infiltration of inflammatory modulators via Kupffer cells 
that result in hepatocyte ballooning, inflammation, and injury. At this point, the disease 
progresses to nonalcoholic steatohepatitis (NASH), which may lead to fibrosis wherein the 
healthy cells are replaced with scarred tissue due to the deposition of collagen. Recent 
findings highlight the promising role of cytokeratin CK 8/18 to be used as a biomarker to 
detect hepatocyte ballooning as their expression is significantly decreased in comparison 
to normal hepatocytes (12), as observed in histological staining. Also, CK-18 fragments 
detected in the plasma positively correlate with the severity of NASH (p < 0.001) (16). 
 NAFLD is observed at a higher incidence in cohorts with metabolic syndrome and 
cardiovascular risk (Fig. 1.1)(17). Additionally, type 2 diabetes mellitus (T2DM) patients 
display a high risk for developing NASH and a 2-to-4-fold risk of developing NAFL. 
Ethnicity also plays a critical role with a higher rate of incidence seen in Hispanics and 
Asians, followed by Caucasians (18). Possession of homozygous PNPLA3 allele 
(rs738409) in the Hispanic population contributes to 2-fold higher hepatic lipid 
accumulation (19). On the other hand, a lower incidence of steatosis is observed in 
African-Americans in comparison to Caucasians. In addition, genetic polymorphism in the 
TM6SF2 gene, involved in VLDL secretion, leads to a higher incidence of NAFLD. The 
variant frequencies in TM6SF2 gene is found to be higher in whites, African-American, 
and Hispanic races (19).  
The occurrence of NAFLD increases with age an incidence of 20% in age group 
under 20 to 40% or more in the age group above 60 (20). Diet enriched with 
macronutrients and carbohydrates posit high risk in developing NAFL as well as its 
progression. It can be worsened when coupled with a sedentary lifestyle and smoking (21, 
22). Moreover, endocrine dysfunction, such as polycystic ovarian disorder (PCOS), is 




show PCOS with insulin resistance worsens hyperandrogenemia, which leads to NAFL. A 
striking association of NAFL is also observed in patients with obstructive sleep apnea 
(OSA), which is caused by a complete or partial obstruction of the airway. The incomplete 
exchange of gases (hypoxemia and hypercapnia) leads to oxidative stress, recruitment of 
pro-inflammatory factors, insulin resistance, and endothelial dysfunction. This may lead to 
the evolution of NAFL to NASH (24). 
3. In vitro models of Nonalcoholic fatty liver disease (NAFLD) 
 
The current in vitro models for NAFLD is summarized in Table 1.1 and the overview of all 
the models are illustrated in Figure 1.2 
3.1 Monoculture systems 
 
3.1.1 Hepatocellular Carcinoma (HepG2, Huh7, and HepaRG) 
Human hepatocarcinoma cell lines have been widely used in the literature to model 
NAFLD in vitro. The ease of propagation, reproducibility, and low cost for procurement 
makes them an ideal candidate for preliminary model development. The majority of the 
models for steatosis have been developed by exposing the cells to free fatty acids, namely 
oleate (OA) and palmitate (PA) (Table 1.1). The choice of these fatty acids stems from the 
high content of oleate and palmitate in triglycerides. Besides, clinical data show varying 
levels of these free fatty acids (FFA) in blood ranging between ∼0.25-3.0 mmol/L, 
moreover, they are chronically higher in individuals with obesity and/or diabetes. 
Acute treatment (24h) with FFA mixture, induced all three cancer cell lines to show 
dose-dependent lipid and triglyceride accumulation; on the other hand, with palmitate 
alone, induced apoptosis, oxidative stress, and insulin resistance. Furthermore, the 




of steatosis (26). Apart from fatty acid stimuli, other models assess the impact of glucose, 
fructose, and insulin on the cell lines to mimic the onset of NAFL, as seen in increased 
intake of dietary macronutrients (27). Lastly, steatosis was assessed in the HepaRG cell 
line stimulated with oleate and palmitate, along with varying concentrations of IL6 (28). 
The presence of IL6 not only induced NAFLD and NASH like phenotype, but also resulted 
in significant downregulation of CYP2A6, 2B6, 2C19, 2C9, 3A4, and 3A5 mRNA after a 
24h treatment (28).  
In context to toxicological assessments, Tolosa et al. (2016) demonstrate the ability 
of HepaRG cell line to appropriately flag the inducers of steatosis upon exposure to 16-
known steatogenic compounds (29).  Furthermore, treatment with tetracycline and 
amiodarone after acute and repeated treatments induced steatosis, highlighting the 
robustness of HepaRG, in predicting the drug-induced hepatotoxicity as well as its utility 
for understanding the molecular mechanisms involved in the onset and progression of 
disease state (7). In summary, these reports represent the possible impact of various 
stimuli on the onset of hepatic steatosis and/or NASH. However, the results from cancer 
cell lines are viewed with skepticism as the translatability of the observed impact on human 
hepatocytes is unknown. In addition, it is well-known that Huh7 and HepG2 cell line 
expresses the drug-metabolizing enzymes in low levels in comparison to human 
hepatocytes (30, 31). Hence understanding the DME modulation could be a challenge. 
However, HepaRG cells can be used to overcome this drawback as evidence show the 
presence of comparable levels of DME to human hepatocytes.   
3.1.2 Primary Human Hepatocytes (PHH) 
Primary human hepatocytes are the current gold standard to study metabolism and 
toxicity related effects of drugs. Donato et al. (2006), showed a model using hepatocytes 




cells were treated with oleate and palmitate to maintain the hepatocytes in the state of 
steatosis for 14 h and 36 h (32). As a result, lipid accumulation and triglyceride increase 
were observed in the hepatocytes with steatosis. In addition, CYP1A2, CYP2A6, CYP2C9, 
CYP2D6, CYP2E1, CYP2B6, and CYP3A4 mRNA, along with CYP1A2, CYP2A6, 
CYP2C9, CYP2D6, CYP2E1, and CYP3A4 enzyme activity showed a significant reduction 
in steatosis (32). This was the first study in which several human P450 enzymes have 
been comparatively examined in a model of induced steatosis. This closely represented 
the disease state; however, the hepatocytes in culture, start to lose their metabolic 
capacity after 72h, and hence, a static, two dimensional (2D)-model cannot be 
representative of long-term impact. 
To mitigate the drawbacks of the 2D static model and to study the long-term impact 
of triglyceride accumulation, three dimensional (3D) spheroids or 3D models using 
scaffolds were developed (33).  The 3D models using scaffolds were cultured in the 
microfluidic device and LiverChip platform with continuous perfusion of media to mimic the 
dynamic sinusoidal flow in the liver (34). This stabilized the hepatic metabolizing capacity 
to over 14 days in culture. Subsequently, the model was treated with control and FFA 
mixture (oleate and palmitate, 2:1) for 7d. As a result, increased levels of secreted 
adipokines were noted; IGFβ1, PDK4, and FABP-1 genes associated with lipid 
metabolism were upregulated; and a decrease in the metabolic rate of CYP3A4 and 
CYP2C9 were also reported. 
3.1.3 Induced Pluripotent Stem Cells derived Hepatocytes (iPSC-Hep) 
Despite the fact that human hepatocytes are considered as gold-standard, they 
represent several limitations, such as donor to donor variability, lack of availability, cost of 
procurement, variability in proliferation, which introduce mutations and polymorphisms in 




(hiPSC-Hep) generated from mature hepatocytes overcome the limitations observed with 
PHH. Henceforth, a model using hiPSC-Hep was co-treated with FFAs (oleate and 
palmitate) and the ER stressor, thapsigargin (TG), to recapitulate NASH (8). This model 
showed intracellular lipid accumulation via activation of denovo lipogenesis as well as its 
association with ER related UPR network. In addition to the genes involved in lipid 
metabolisms such as SREBP-1c, ACC1, and SCD1, and known markers of NASH such 
as STC2 and FGF21 were upregulated. Henceforth, this model showed the potential to 
induce NAFL and NASH successfully. Additionally, hiPSC-Hep demonstrates an added 
advantage of having the potential to derive genotype-specific hepatocytes from patient 
samples to understand the relevance of polymorphic genes (PNPLA3) in the signaling 
network. 
3.2 Co-culture systems 
3.2.1 Micropatterned Primary Co-Cultures (MPCCs) 
To maintain the longevity of primary human hepatocyte in culture, MPCCs were 
developed to study the effects of hyper and hypoglycemia in hepatocytes. MPCCs 
recapitulate the homotypic interactions with the primary human hepatocytes as well as the 
heterotypic interactions of hepatocytes with supportive non-parenchymal cells (NPCs) 
such as fibroblasts (35). MPCC model was facilitated by patterning 24-well plated with rat-
tail collagen 1 at 500 µm diameter spaced 1200 µm away from each other. This enabled 
the selective attachment of hepatocytes to collagen islands along with the 3T3-J2 
fibroblasts covering the spaces between the islands. This study, for the first time, showed 
the culture of PHH with fibroblasts, stabilized the PHH in culture for ~3 weeks, and was 
used to understand the response to chronic treatment with varying concentrations of 
glucose (35). Upon treatment with high glucose, insulin-responsive genes SREBF1 and 




suggesting the shuttling of glucose to insulin-stimulated lipogenesis in the cells. Also, 
hyperglycemia downregulated CYP2E1 transcripts. This model showed ‘selective’ insulin 
resistance akin to type 2 diabetes mellitus (T2DM). 
3.2.2 MPCCs with activated stellate cells 
MPCCs were constructed with activated or growth arrested human stellate cells 
(HSCs) as the supportive cell type (1 HSC: 12 PHHs using 2.5k HSCs) along with human 
hepatocytes (36). The addition of proliferative stellate cells resulted in an increase in 
albumin production and CYP3A4 activity in hepatocytes. However, severe distortion of 
hepatocyte islands occurred in 2 weeks. Showing that the activated HSCs, proliferative or 
growth-arrested, cannot support PHH functions to the same extent of 3T3-J2 fibroblasts. 
3.3 Tri-culture systems 
3.3.1 Micropatterned Tri-Cultures (MPTCs) 
To stabilize the hepatocytes in long-term culture as well as induce NASH-like 
phenotype with activated stellate cells, a micropatterned tri-culture model was introduced. 
In this model, growth-arrested 3T3-J2s (90k cells per 24-well format) were mixed with 
activated HSCs (2.5k), and this mixture was then seeded onto to micropatterned PHH 
colonies (30k cells) (36). The ratio of stellate cells to PHH was corresponding to the 
proportion in the human liver. In such micropatterned tri-cultures (MPTCs), albumin 
secretion was higher than the levels seen in MPCCs. Besides, the supporting non-
parenchymal cells (NPCs) stabilized the hepatocytes in culture. Upon the stimulus from 
activated stellate cells for 13 d, significant levels of lipid-filled vesicles (containing acyl-
glycerols and cholesterol esters) were observed. Besides, the upregulation of IL6 and 
CRP protein, as seen in NASH, was observed. Downregulation of significant liver-specific 
genes was observed, such as PXR, CAR, CYP3A4, CYP2A6, NTCP, MRP2, BSEP, and 




with the upregulation in the mRNA of LOX and COL1A1 (36). In summary, MPTCs show 
NASH/fibrosis like phenotype. Despite the well-maintained architecture, the model 
occasionally induced distorted hepatocyte islands due to donor-to-donor variability. 
Henceforth, human hepatocytes, and stellate cell lots in the development of this model 
must be chosen after careful screening.  
3.3.2 Trans-well culture  
An in vitro model with the combination of coculture of stellate cells and fibroblasts in 
trans-well and monoculture on hepatocytes in the culture plates was developed to model 
NASH. The separation of stellate cells and fibroblasts from hepatocytes helped in 
understanding the specific impact on hepatocytes. In addition to the culture, the model 
was engineered to incorporate hemodynamic stress, hepatic sinusoidal flow, transport, 
and finally exposed to lipotoxic risk factors such as glucose, insulin, free fatty acids (oleate 
and palmitate) (37). Upon the stimulus, hepatocyte glucose output increased with 
decreased insulin sensitivity. Increased levels of IL6, IL8, and ALT were observed along 
with the activation of fibrogenic markers such as TGF-ß. This model showed 
transcriptomics, proteomics, and lipidomics signature similar to that of NASH liver 
biopsies. 
3.4 Multi cell-culture systems 
3.4.1 3D-Human Liver Micro-Tissues (3D-hLMT)  
3D-hLMT model is the known closest in vitro culture system that mimic the in vivo 
liver physiology. The model can recapitulate the multicellularity in 3D format and maintain 
individual cell phenotype for over 5 weeks (38). PHH were co-cultured with NPCs such as 
hepatic stellate cells, Kupffer cells, and endothelial cells. In this model, 0.5 mM of palmitic 
acid (PA) induces a robust inflammatory as well as fibro-genic response in the 3D-hLMT. 




transcripts, as well as TGFβ gene activation pathway (38). Nevertheless, owing to its 
complexity, these models are time-consuming and expensive to establish; in addition, 
scalability is a limiting factor to use these models in routine high-throughput screening. 
3.4.2 Induced Pluripotent Stem Cell (iPSCs) derived organoids  
iPSCs derived from 11 human donors (healthy and diseased) were developed to 
derive organoid comprising of hepatocyte, stellate, and Kupffer and biliary-like cells whose 
genetic signature was confirmed from transcriptomics analysis. Upon stimulus with fatty 
acids (800 µm of oleate) for 5 days, the human liver organoids (HLO) showed the stepwise 
progression of NAFLD from steatosis, ballooning, inflammation, and fibrosis phenotypes 
recapitulating NASH in the latter stages (39). In addition, atomic force microscopy 
confirmed the severity of fibrosis conferred in the HLOs. This novel approach sets a unique 
benchmark to understand the genotype-specific contributions on the progression of 
disease state as well as contribute to therapies based on personalized treatment. 
However, the significant limitations associated with this model must also be taken to 
account. The donor to donor variability might affect the HLOs phenotype, such as NASH 
and fibrosis (39). Additionally, the time and cost involved in the organoid development may 
pose further limitations in routine usage. 
3.5 The organotypic ex-vivo culture system 
3.5.1  Precision-Cut Liver Slices (PCLS) 
Many advancements have been noticed in the use of 2D and 3D monoculture to mimic 
NAFLD. However, the complex interactions of multiple cell types such as hepatocytes, 
Kupffer cells, stellate, and endothelial cells that induce inflammation, necrosis, and 
consequently, fibrosis in NAFLD, is impossible to be recapitulated in a 2D and 3D-
monoculture. Human precision-cut liver slices (hPCL) retain the liver architecture with the 




lymphocytes to up to 5 days in culture (40). Henceforth, they make an excellent model to 
study the changes observed during the different stages of NAFLD and test new therapies. 
hPCLS model for NAFLD is developed as follows: (1) Resected liver tissue flushed 
with ice-cold University of Wisconsin (UW) solution and ~ 1 cm thick tissue is prepared for 
further processing. (2) Following this, a hollow cylindrical tissue drill is used to prepare 
chunks of 5 mm diameter cores. (3) The cores are inserted in the tissue holder and cut 
with the microtome (Krumdieck Tissue Slicer). (4) Liver sections of 5 mg weight and ~ 250 
µm thick are prepared for further treatments. (5) hPCLS are treated with free fatty acids 
(a mixture of oleic and linoleic acids, 0.1 mM) to mimic the hepatic steatosis, lipid 
deposition, and lipotoxicity. Alternatively, opportunities to prepare hPCLS from cirrhotic 
patients to assess therapeutic interventions also exist for future development. PCLS 
makes ideal models, especially by maintaining the intact morphology of hepatocytes. 
However, the limited time in culture and the inability to adapt to genetic changes such as 
transfection or RNA silencing, makes it challenging to understand the impact of a specific 
gene in the signaling pathways leading to disease progression.  
4. Conclusion 
 
A translatable human in vitro model of NAFLD is the need of the hour. However, a 
model that fits all-purpose, to study a "multiple-hit" disease state, such as NAFLD, poses 
a highly relevant challenge to the research community. The majority of models developed 
thus far represent 2D-static mode involving either PHH or human carcinoma cell lines. 
However, it is impossible to study the whole spectrum of disease state using such simple 
systems. Hepatic steatosis was well recapitulated using various stressors, such as free 
fatty acids, glucose, and fructose, insulin, interleukins as well as other chemicals. A few 
studies have advanced further, by including microfluidic the model to mimic the sinusoidal 




the supporting NPCs. Sophisticated models with 3D-hLMT as well as iPSC-derived 
organoids, only show a sneak-peak of the innovations coming up soon. This may allow for 
the whole body to be modeled on the chip to understand the disease state beyond the 
liver, by including the gut axis as well as adipose tissue. Such innovative tools will 
contribute to new therapies as well as understanding other complexities that come with 





5. Figures and Tables 
  
 
Figure 1. 1: Risk factors associated with nonalcoholic fatty liver disease. 
Abbreviations. NAFLD: Nonalcoholic fatty liver disease; NASH: Nonalcoholic 
steatohepatitis; T2DM: Type 2 diabetes mellitus; PCOS: Polycystic ovarian syndrome; IR: 






Figure 1. 2: In vitro models of nonalcoholic fatty liver disease. 

































Table 1.1: Preclinical in vitro model for NAFLD. 















  Palmitate 
conjugated to 
BSA (5:1)  
8 mM 24 h ↑ Lipid accumulation; ↑ TG 




  Oleate: Palmitate 
(1:1; 2:1, 0:3) 
conjugated to 
BSA 





  Valproate  1, 2.5 and 5 
µM 
24 h Concentration-dependent 
increase in intracellular fat; ↑ 










  24h and 48 
h 
↓ Lipid accumulation and TG 
than 2D static model.  
NAFLD (45) 
Huh7 Glucose only or 
Glucose and 
Fructose (G: F) 
(1:1) 
0.65-0.72 







G: F treatment ↑ TG 








  Palmitate 0.2 - 0.8 mM 8 h ↑ ER stress Progression to 
NASH 
(46) 
  Oleate: Palmitate 
(2:1) 
0.2 mM 24 h ↑ Lipid accumulation; 
↑IL8; ↑IL6 and TNF alpha 
secretion 
NASH (47) 
  Oleate: Palmitate 
(1:1) 
0 - 1.2 mM 24 h ↑ Lipid accumulation Hepatic 
Steatosis 
(46) 
HepaRG 6 negative 
control and 8 
steatotic 
compounds 
Based on the 
compound  
24 h Steatotic compounds: ↑ lipid 
accumulation and ↑ ROS 
production. ↑ gene 
expression of EHHADH 
CROT MTTP ANGPTL3 





  Tetracycline and 
amiodarone 
0-0.1 mM of 
tetracycline; 
0-0.02 mM of 
amiodarone 
0 and 14 d ↑ Lipid accumulation; ↑TG 





  Bisphenol a 0.2 - 2000 
nM 





  Stearic acid or 
Oleic acid with 
insulin treatment 
0 - 0.1 mM 7 d ↑TG and lipid-responsive 









  Oleate: Palmitate 
(2:1); Palmitate 
alone 
0.5 mM 48 h ↑ Lipid accumulation; ↑TG; ↑ 
carnitine metabolism; 
Palmitate alone contributed ↑ 
insulin resistance; Palmitate 











  Oleate: Palmitate 
(1:1) along with 
IL6 
0.125 mM + 
10 ng/mL of 
IL-6 
14 d or  
24 h 
IL-6 in 24 h ↓ CYP 1A2, 2A6, 
2B6, 2C19, 2C9, 3A4 and 
3A5 gene expression; O/P in 









0.25 - 3 mM 14 h ↓ CYP 1A2, 2A6, 2C9, 2D6, 





3D spheroids from PHH  Oleate: Palmitate 




160 - 320 µM 48-72h ↑ Lipid accumulation; ↑TG 
accumulation with steatosis 
reversibility in absence of 






cultured into 3D model 
using scaffolds and 




0.6 mM  14 d ↓ CYP 3A4 and 2C9 enzyme 
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insulin (I) and 
Palmitic acid 
(PA) 
25 mM (G), 5 
mM (F), 1 
mM (I), 240 
!M (PA) 









hepatocytes plated in 
collagen coated islands 
along with 3T3-J2 
fibroblasts 
Glucose 0.5 mM - 25 
mM 
10 d and 18 
d 
↑ Albumin secretion; ↑ Urea 
synthesis; ↑ lipid 
accumulation; ↑ CYP3A4, 
2A6, 2D6 mRNA and ↓ 
CYP2E1 mRNA; selective 








hepatocytes plated in 
collagen coated islands 
along with hepatic 
stellate cells (HSCs). 
90K HSC:30K 
PHHs in 24 well 
format 
  14 d ↑ CYP3A4 and 2A6 activity; ↑ 
albumin secretion; ↑ 
distortion of hepatocyte 












macrophage (top of 
transwell) and 
hepatocytes (bottom of 
the transwell) 
incorporated with 
hepatic sinusoidal flow 
Insulin, glucose, 










10 d  ↑Lipid Accumulation; ↑ De 
novo lipogenesis and 
cholesterol synthesis; ↑ IL-8 




culture (MPTC): Primary 
Human hepatocytes 
plated in collagen 
coated islands along 
with 3T3-J2 fibroblasts 
and hepatic stellate 
cells (HSCs) in inserts. 
Glucose 5 mM 14 d ↑ Albumin secretion; ↑ Urea 
synthesis; ↑ lipid 
accumulation; ↑ CYP3A4, 
PXR, CAR mRNA and ↓ 
CYP3A4 and 2A6 enzyme 
activity; ↓ NTCP, MRP2 and 
BSEP mRNA; ↑ IL6 and C-RP 
secretion and selective 














cells such as hepatic 
stellate cells, Kupffer 
cells and endothelial 
cells  
Palmitate 0.5 mM 9 d ↑ IL8 imaging; ↑ pdgfr" gene 
expression; ↑ TGFβ pathway; 






11 healthy and diseased 
pluripotent stem cells 
used in developing 
reprogrammed 
organoids composed of 
the hepatocyte, stellate, 
biliary-like and the 
kuffer cells.  
Oleate 0.8 mM 5 d ↑ Lipid accumulation; ↑TG 
accumulation; ↑IL6; ↑ 
hepatocyte ballooning; ↑ 
inflammation and fibrosis 
associated genes; ↑ stiffness 
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Background & Aim. Human hepatic carcinoma cell lines are commonly used in invitro 
studies of lipid and xenobiotic metabolism, as well as glucose regulation in normal and 
disease state. However, their validity is still under debate due to the variable expression 
of proteins in the cell lines and human hepatocytes. In this present study, we used a data 
independent acquisition based total protein approach (DIA-TPA) to quantify the protein 
abundance in the different cell lines versus (vs.) human hepatocytes (cHH) and human 
liver tissue (HLT). For this purpose, the global proteome from the whole cell homogenates 
of HepaRG, HepG2, Huh7 cell lines were compared to cHH and HLT.  
Methods. In-solution trypsin digestion of proteins in whole cell homogenate was conducted 
using pressure-cycling technology (PCT). DIA was carried out by sequential window 
acquisition of theoretical mass spectra (SWATH-MS). In addition, MS2 spectra for all 
detectable peptides at its corresponding m/z were quantified using Spectronaut™, which 
was then analyzed using TPA. 
Results. In summary, 2715, 2578, 2874, 2717 and 3083 proteins in, HepaRG, HepG2, 
Huh7, cHH and HLT, were identified at 1% FDR, respectively. The global proteome of the 
cHH significantly differed from the cancer hepatic cell lines. Within the cell lines, the global 
as well as ADME protein profile of HepaRG most closely correlated with cHH, with 84 out 
of 101 ADME proteins, identified in HepaRG cells. Within gluconeogenesis and glycolysis 
pathway, Huh7 cell line expressed proteins in high abundance in contrast to the other 
groups.  
Conclusion. In summary, the comparison demonstrates the capability of untargeted global 
proteomics to detect the differences in protein expression among the different groups. In 
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The human liver is the major organ for metabolism and clearance of xenobiotics, 
maintenance of glucose homeostasis as well as regulation of lipid metabolism.1 Majority 
of the circulating proteins in the plasma, such as albumin, that constitutes 55-70% of 
human plasma is produced by the liver. Liver also play a central role in the excretion of 
bile and cholesterol. The diverse metabolic and secretory function of the liver is aided by 
the presence of specialized cell types such as hepatocytes, kupffer, stellate and biliary 
endothelial cells. However, 80% of the tissue is comprised of the hepatocytes alone.2 The 
hepatocytes are mostly binucleated3 and contains abundant proteins localized to 
endoplasmic reticulum and mitochondria, indicating their effective role in protein synthesis 
and energy metabolism, respectively.  
In hepatocytes, the glucose consumption is observed via the uptake of plasma 
glucose, followed by the break-down of the sugar moiety to pyruvate, which in-turn is 
oxidized through the TCA cycle to produce ATP. Conversely, the glucose may also get 
converted to fatty acids via de-novo lipogenesis pathways.4 On the other hand, 
hepatocytes also play a critical role in lipid metabolism via conversion of non-esterified 
fatty acids into tri-acylglycerols (TAG), which in-turn is stored or secreted as low-density 
lipoproteins (VLDL) back into the plasma.4 Studies characterizing the mechanisms 
involved in metabolic functioning of the liver, in the healthy as well as disease state such 
as obesity, insulin resistance, non-alcoholic fatty liver disease (NAFLD) are on the 
increase.5-8 The gold standard for such invitro studies are human hepatocytes. However, 
the cost of procurement, donor-to-donor variability as well as limited availability renders 
some disadvantages of using them for long-term studies. Consequently, hepatic 
carcinoma cell lines such as HepG2, Huh7 and HepaRG cells are often used as an 




in toxicity as well as drug metabolism assays in preclinical studies.9-11 However, it is 
unclear how well the tumor-derived cell lines represent the human hepatocytes in-context 
to their protein expression involved in lipid and energy metabolism as well as xenobiotic 
metabolism. 
Shotgun proteomics is a powerful tool for analyzing proteolytic peptides of high 
intensity, from low-throughput biological assays. The results generated are high-
throughput and have a complete proteome coverage that out-weighs the traditional labor 
and resource intensive western blotting techniques.2,12 Data-dependent acquisition (DDA) 
has been used more commonly in untargeted analysis.13 However, bias associated with 
the abundant peptides and the lack of sensitivity to quantify low-abundance proteins, 
renders limitation to use this approach.14 Hence, sequential window acquisition of all 
theoretical mass spectra (SWATH-MS) that follows a Data Independent Acquisition (DIA) 
was employed to analyze the samples. Eventually, the DIA based total protein approach 
(DIA-TPA) was used to compare the absolute protein levels of the human hepatocytes 
and the carcinoma cell lines.15-17 This approach is sensitive to capture the low abundant 
proteins which makes it ideal to compare the expression pattern of thousands of proteins 
from the cell lines and human hepatocytes, at the same time. In addition, we compared 
the protein expression from whole cell homogenate without enrichment. We believe this 
novel approach of sample analysis overcomes the limitation of loss of proteins in 
fractionation and enrichment and is more reflective of the biological state.2,18,19 
The objective of this study was to compare the protein expression involved in the 
glucose, lipid as drug metabolism pathways in immortalized hepatocyte cell-lines as well 
as primary human hepatocytes. This comprehensive comparison provides a database to 





2. Materials and Methods 
2.1. Chemical and Reagents 
Trypsin digested β-galactosidase (E. coli) (Catalog No. #4445247) and TPCK-treated 
trypsin (Catalog No. #4445250) was procured from Sciex (Framingham, MA). Bovine 
serum albumin (BSA) (Catalog No. #23209) and Iodoacetamide (IAA) (Catalog No. 
#I6125), Dithiothreitol (DTT) (Catalog No. #DTT-RO), Ammonium bicarbonate (Catalog 
No. #40867) and Sodium deoxycholate (DOC) (Catalog No. #30970) were purchased from 
Sigma-Aldrich (St. Louis, MO). MS grade acetonitrile (Catalog No. #A955), methanol 
(Catalog No. #A456), choloroform (Catalog No. #C297) and formic acid (Catalog No. 
#A117) were from Fisher-Scientific (Hampton, NH). Acquity UHPLC Peptide BEH C18 
analytical column (Catalog No. #186005594) and VanGuard precolumn (Catalog No. 
#186004629) were from Waters Corp. (Milford, MA).  
2.2. Cell Culture 
The cell lines and cHH were cultured as per conditions in-house or as per manufacturer’s 
protocol. The conditions between the different cell lines and cHH were maintained as close 
as possible with minor changes that conformed to specific cell lines and cHH. 
Cryopreserved primary human hepatocytes (cHH). Three donors of cHH, namely lot, 
LQG, AQL, VHB were obtained from Bio ReclamationIVT (Baltimore, MD) (Table 2.1) were 
thawed in InVitro GRO CP media (Bio ReclamationIVT, Catalog No. #Z99029, Baltimore, 
MD) and viable cells were counted using Tryphan-Blue (Sigma-Aldrich, Catalog No. 
#T8154, St. Louis, MO) exclusion method. The cells were seeded in collagen coated 6-
well plate (Corning Inc., Catalog No. #354400, Corning, NY) at a seeding density of 0.7 
million cells per well. After 4 h of plating, cells were washed and incubated using CP 
media, to remove cell debris. Following 24 h of incubation at 37°C, cells were extracted 




#229310, Pepperell, MA) in ice-cold DPBS (ThermoFisher Scientific, Catalog No. 
#14040117, Waltham, MA) and 10-million cells from each lot was pooled for further 
analysis. It was found that the cell attachment efficiency varied from donor to donor. 
However, all lots were approximately 90% confluent before cell extraction. 
HepG2 cells. HepG2 cells were purchased from American Type Culture Collection 
(Manassas, VA). The HepG2 cells were cultured in Eagle’s Minimum Essential Media 
(Sigma-Aldrich, Catalog No. #M2279, St. Louis, MO) supplemented with 10% FBS 
(Sigma-Aldrich, Catalog No. #F2442, St. Louis, MO), 1% penicillin/streptomycin 
(ThermoFisher Scientific, Catalog No. #15140122, Waltham, MA). Cell passage (6 & 7) 
was performed with Trypsin-EDTA (ThermoFisher Scientific, Catalog No. #25200072, 
Waltham, MA) when HepG2 cells were 80% confluent in culture. The cells were cultured 
in 25 cm2 flask (Sigma-Aldrich, Catalog No. #CLS430639, St. Louis, MO) for 24h, before 
subjected to cell extraction for proteomics analysis. Approximately 8-10 million cells were 
cultured and harvested by cell scraping. 
HuH7 cells. Huh7 cell line was kindly provided by Dr. Nisanne Ghonem (University of 
Rhode Island). Cells were cultured in Dulbecco’s Modified Eagle Media (ThermoFisher 
Scientific, Catalog No. #11320082, Waltham, MA) supplemented with FBS and 1% 
penicillin/streptomycin. The concentration of FBS was maintained at 10% until cells 
reached confluence. Upon confluence, cells were maintained for 3 weeks in 1% FBS.11 
Cell passages (4 & 5) were performed with 0.25% trypsin-EDTA when cells reached 90% 
confluence in 25 cm2 flask. Approximately 8-10 million cells were cultured and harvested 
by cell scraping. 
HepaRG cells. Frozen undifferentiated HepaRG cells were purchased from Biopredic 
International (Rennes, France). The cells were grown for 2 weeks in William’s E media 




glutamine (ThermoFisher Scientific, Catalog No. # A1286001, Waltham, MA), 1% 
penicillin/streptomycin and 10% HepaRG growth supplement (Lonza Inc., Catalog No. 
#ADD711C, Walkersville, MD) in 6-well plate. Following growth phase, cells were 
differentiated in-house for 2 weeks in William’s E media, 1% glutamine, 1% 
penicillin/streptomycin and 10% HepaRG differentiation supplement (Lonza Inc., Catalog 
No. #ADD721C, Walkersville, MD) and maintained at 37°C with 21% O2 and 5% CO2 
throughout the culture with media changed every 3 days. Upon differentiation, HepaRG 
cells were cultured in basal media containing William’s E media, 100 U/mL penicillin, 100 
µg/mL streptomycin, 2 mM glutamine, 5 µg/mL insulin (Sigma-Aldrich, Catalog No. #I-034, 
St. Louis, MO) and 50 µM hydrocortisone hemisuccinate (Sigma-Aldrich, Catalog No. 
#H2270, St. Louis, MO). Approximately 8-10 million cells were cultured and harvested by 
cell scraping for proteomic analysis.  
Human Liver Tissue. 100 mg of frozen human liver samples (n=3) from brain dead 
donors were purchased from Sekisui XenoTech LLC (Kansas City, KS). The detailed 
demographics of the donors are given in Table 2.1. Livers were graded by a 
histopathologist as previously described20 and were categorized as normal, healthy livers. 
2.3. Whole cell homogenate and proteomics sample preparation  
An overview of the study workflow is given in Fig. 1. Cells scraped and collected in DPBS 
was centrifuged at 300g at 4°C for 10 min. The cell pellets obtained was washed in DPBS 
as mentioned above. Approximately 8-10 million cells from each group was pooled and 
homogenized in 1000 µl of homogenization buffer (8 M urea, 50 mM Triethylammonium 
bicarbonate, 10 mM DTT v/v) using a bead homogenizer (Omni Bead Ruptor 24, 
Kennesaw, GA). In addition, 50 mg of liver tissue was homogenized in 1000 µl of 
homogenization buffer, in similar fashion. Samples were then spun at 1,000 g for 5 min 




was determined using Pierce BCA protein assay kit (ThermoFisher Scientific, Catalog No. 
#23227, Waltham, MA).  
2.4. In-solution trypsin digestion  
Protein digestion was conducted as described previously with few adaptations.21,22 
Samples (250 µg protein) were spiked with 2 µg of BSA and denatured with 25 µL of DTT 
(100 mM) at 35°C for 30 min in a shaking water bath (100 rpm) (Precision Scientific, 
Catalog No. #66800, Chicago, IL). After denaturation, samples were alkylated in the dark 
with 25 µL of IAA (200 mM) for 30 min at room temperature. Samples were then 
concentrated using the cold water, methanol and chloroform (1:2:1) precipitation method 
(centrifugation at 10000 rpm, 5 min at 10°C) (Eppendorf, Catalog No. #5810 R, Hamburg, 
Germany). The protein pellet was washed with ice-cold methanol and suspended in 100 
µL of 50 mM ammonium bicarbonate (pH ~8) containing 3% w/v sodium deoxycholate 
(DOC). Further, TPCK-treated trypsin (10 µg) was added to samples at a ratio of 1:25 
(trypsin: protein) and samples were transferred into digestion tubes (PCT MicroTubes, 
Pressure Biosciences Inc., Easton, MA). The barocycler was run at 35°C, for 75 cycles 
with 60-sec pressure-cycle (50-sec high pressure, 10-sec ambient pressure, 25 kpsi). 
Subsequently, 10 µg trypsin was again added to each sample and digestion was repeated 
as mentioned above. 
Furthermore, to 110 µL of digested peptides sample, 10 µL of acetonitrile (1:1, v/v 
containing 5% formic acid) was added to precipitate DOC. Samples were spun (10,000 
rpm for 5 min at 10°C) to remove the precipitate and 100 µL supernatant was collected. 
Subsequently, 25 µL of the digested peptide sample was injected on the analytical column 




2.5. LC-MS/MS Analysis 
Data-dependent analysis (DIA) was performed in positive ionization mode using a 
DuoSpray™ ion source on a Sciex 5600 TripleTOF™ mass spectrometer (AB Sciex, 
Concord, Canada) equipped with an Acquity UPLC HClass system (Waters Corp., 
Milford, MA, USA).  Gas 1 (GS1), gas 2 (GS2) and curtain gas (CUR) were maintained at 
55, 60 and 25 psi, respectively.  Ion spray voltage floating (ISVF) was kept at 5500 V while 
the source temperature (TEM) was 500°C. Declustering potential (DP), collision energy 
(CE) and collision energy spread (CES) were set at 120, 10 and 5 respectively. During the 
survey scan, all the ions with a charge state of 2 to 4, mass range of m/z 300-1250 and 
exceeding 25 cps were used for MS/MS analysis. Former target ions were excluded for 8 
sec and the mass tolerance for TOF-MS was 50 mDa with a 100 milliseconds 
accumulation time. For product scan, data were acquired from 100 to 1250 m/z with an 
accumulation time of 75 milliseconds with a total cycle time of 3.5 sec. Product ion analysis 
was done under dynamic accumulation and rolling collision energy dependent on the m/z 
of the ion. 
Chromatographic separation was achieved over 180 min gradient method at 100 μL/min 
on an Acquity UPLC Peptide BEH C18 (2.1 X 150 mm, 300 Å, 1.7 µm) preceded by an 
Acquity VanGuard pre-column (2.1 X 5 mm, 300 Å, 1.7 µm). Mobile phase A was 98% 
water, 2% acetonitrile, 0.1% formic acid and mobile phase B was 98% acetonitrile, 2% 
water, 0.1% formic acid).  Gradient conditions used were 98% A from 0 to 5 min, 98% 
to 70% A from 5 to 155 min, 70% to 50% A from 155 to 160 min, 50% to 5% A from 160 
to 170 min, 5% to 98% A held from 170 to 175 min. The gradient was held at initial 
conditions from 175 min until the end of the run to equilibrate the column before the 
start of next run.  The flow was diverted to waste for the first 8 minutes and last 20 minutes 




50°C. Trypsin-digested β-galactosidase peptides were injected to monitor TOF detector 
mass calibration every four samples. 
2.6. SWATH-MS acquisition and data analysis  
Homogenate samples were analyzed using SWATH-MS based spectra which were 
acquired for mass range m/z 400−1100 Da within SWATH window width of 10 m/z 
resulting in 70 overlapping mass windows per cycle, as described in the previous 
literature21. The DIA data was searched against Swiss-Prot identifiers (October 2016) and 
analyzed using Spectronaut™ Pulsar software (version 11.0, Biognosys AG, Schlieren, 
Switzerland) was used to obtain MS2 signal intensities of fragment ions from DIA data 
using default settings with a few modifications that includes specific trypsin/P digestion 
with a minimum of 7 amino acids, maximum of 52 amino acids and 2 missed cleavages; 
fixed modifications included carbamidomethyl (C) and variable modifications included 
acetyl (protein N-terminus) and oxidation (M). Raw data files and search results are 
available at Japan Proteome Standard Repository (jPOSTrepo JPST000372, 
ProteomeXchange PXD008593). The SWATH-MS DIA data was matched with the 
reference spectral library generated from the DDA of pooled human liver samples using 
Protein Pilot. The DIA data was then normalized and analyzed using “Total protein 
approach” (TPA), as shown below (1).  
          … (1) 
The absolute protein abundance of each group was represented as pmol/mg of protein. 
2.7. Statistical and bioinformatic analysis  
A number of normalization strategies were tested using NormalyserDE. LIMMA package 




log2FC <0.58) to identify differentially expressed proteins. Differentially expressed 
pathways associated between human hepatocytes, and the three hepatocarcinoma cell 
lines was assessed using ingenuity pathway analysis (Ingenuity Systems, Redwood City, 
CA, USA). PCA analysis was conducted using Perseus (version 14.1, MKS Umetrics). 
Hierarchical clustering was calculated using Euclidean distance metric was conducted 
using Spectronaut™ Pulsar software. Venn diagram was drawn using an online tool 
(http://bioinformatics.psb.ugent.be/webtools/Venn/). GraphPad Prism (version 8.0) was 
used in data visualization and statistics. The Phase I, II and transporters protein 
expression among the different groups were analyzed using one-way ANOVA and post-
hoc analysis of multiple comparison Bonferroni test was carried out to assess significance 





3.1. Global proteome profile comparisons from DIA data among the whole cell lysate of 
human hepatocytes, human liver tissue as well as the HepaRG, HepG2 and Huh7 cell 
lines 
As illustrated in the overall workflow (Fig. 2.1), DIA data was first generated from 
the whole cell lysate samples of human hepatocytes (lot LQG, AQL, VHB), human liver 
tissue (510, 758 and 791) and three hepatic cell lines, namely, the HepaRG, HepG2 and 
Huh7. As a result, 2715, 2578, 2874, 2717 and 3083 proteins in, HepaRG, HepG2, Huh7, 
cHH and HLT, were identified at 1% FDR, respectively (Table 2.2). It is to noted that, 153 
(7.2%) proteins in HepaRG was found to be common with HLT and not with cHH (Fig. 
2.2B), and we believe this is due to the bipotent progenitor status of HepaRG, resulting in 
expression of hepatocyte-like and biliary-like cells. 
In addition, the global proteome profiles of the cell lines, cHH and HLT were 
analyzed using Perseus and represented as a PCA and heat map (Fig. 2.3B). Dramatic 
differences were observed between cHH, HLT and the three cell lines. With regard to the 
PCA analysis of component 1 and 2, it was noted that the HLT and cHH were grouped 
closer to one another in comparison to the hepatic carcinoma cell lines. In addition, 
hierarchical clustering (Fig. 2A) showed a similar pattern of the HLT and cHH grouped 
together with minimum distance and hepatic carcinoma cell lines were clustered closer to 
one another. 
3.2. SWATH-MS analysis of ADME protein expression in the HLT, cHH and the hepatic 
cell lines 
To investigate the detection reliability, we performed label-free quantification on 




(2647 out of 2717) were found in both sample types. Overall, a good global correlation in 
protein abundance of individual proteins were observed between the two sample sets. In 
addition, we detected 89 out of the 101 ADME proteins (88%) chosen from the literature. 
The ADME protein abundance, showed a good correlation around the line of unity. 
The hepatic cell lines correlated moderately with the hepatocytes with 2309 (85%), 
2174 (80%), 2308 (84%) of the global proteins from HepaRG, HepG2 and Huh7 matched 
with 2717 proteins of cHH, respectively. Similarly, we detected 92 (91%), 70 (69%) and 
74 (73%) out of the 101 ADME proteins, respectively. HepaRG, showed a more 
comparable levels of ADME proteins (Fig. 2.4B), however Huh7 and HepG2 showed a 
distribution of ADME proteins below the line of unity showing lower expression in these 
cell lines in comparison to hepatocytes (Fig. 2.4C and D). 
3.3. SWATH-MS analysis of proteins involved in energy and lipid metabolism in the HLT, 
cHH and hepatic cell lines 
Hepatocytes are pivotal in the energy supply and storage. The major pathways 
such as glycolysis/gluconeogenesis, are involved in the conversion glucose to pyruvate, 
eventually for ATP production (Fig. 2.5). Glucose undergoes phosphorylation by 
hexokinase or glucokinase to form glucose-6-phosphate (G6P) that is converted to ATP 
via glycolysis. Furthermore, via gluconeogenesis, pyruvate is converted to acetyl-CoA that 
participates in ATP production as seen in TCA cycle. Alternatively, glucose is also used 
up in lipid synthesis via pentose-phosphate pathway. 
The protein expression in terms of energy metabolism varied significantly in HLT, 
cHH and the hepatic cell lines (Fig. 2.6). For instance, the primary enzyme involved in 
gluconeogenesis, 1,6-glucose bisphosphatase (FBP1/2), was identified only in cHH and 




were found in higher abundance (~6 fold) in cHH than HepaRG cell lines. Hexokinase 
(HK1), important enzymes involved in glycolysis was present in HLT, cHH and was 
comparable to the levels in HepaRG cell line. In contrast, LDHA involved in the conversion 
of lactate (released by the muscles) to glucose in hepatocytes was found in high 
abundance in Huh7 cell lines (9-fold) in comparison to cHH (Fig. 2.6). There is some 
evidence in literature, showing the ability of cancer cells to be reprogrammed to utilize 
glycolysis at higher rates, in support to this we observed higher abundance of majority of 
enzymes (ENO1, GAPDH, PGAM1, PGK1, PKLR, PKM, TPI1) in Huh7 cell line in 
comparison to cHH (Table 2.3).23 
The non-esterified fatty acids (NEFA) released from the adipocytes are taken up 
by the hepatocytes and ligated to CoA that initiates the metabolism of fatty acids or triacyl 
glyceride (TAG) synthesis. This process is carried out by different isoforms of ACSL, 
namely 1,3 and 5. In cHH and HLT the most abundant form was noted to be ACSL1 and 
the levels were comparable to HepaRG cell line. However, the isoform ACSL3 and ACSL5 
play a predominant role in HepG2 cell line (Fig. 2.5). The fatty acids with more than 16 
carbon chain may preferentially undergo peroxisomal oxidation. Enoyl-CoA Hydratase 
and 3-Hydroxyacyl CoA Dehydrogenase (EHHADH), key enzyme involved in fatty acid 
beta-oxidation was measured as 17.1 pmol/mg which was similar to HLT and 2-fold higher 
than HepaRG (8.5 pmol/mg) cell line (Table. 2.4) Among the hepatic cell lines, HepaRG 
cell line showed highest protein abundance of the groups of protein involved in both 
peroxisomal and mitochondrial beta-oxidation in comparison to Huh7 and HepG2 cells 
and was more comparable to cHH.  
3.4. SWATH-MS analysis of proteins involved in xenobiotic transport and drug metabolism  
Liver is the major organ that contributes to clearance and metabolism of drugs and 




metabolizing enzymes present in the hepatocytes. The drugs in the circulations are taken 
up by the hepatocytes via basolateral uptake transporters (Fig. 2.9A), followed by phase I 
and/or phase II metabolism (Fig. 2.7 and 2.8), and eventually the metabolites are excreted 
back into the blood or bile (Fig. 2.9B) to be eliminated by the kidney or the intestine, 
respectively. In general, solute carrier (SLC) family facilitate uptake of xenobiotics from 
the blood, while the efflux of compounds from hepatocytes are carried out by the ATP-
binding cassette (ABC) family. It is to be noted, that our findings showed the most 
abundant uptake transporters detected in cHH and HLT were organic anion transporter 2 
(OAT2), organic anion transporting polypeptide 1B1 (OATP1B1), and OATP1B3 at around 
4.0, 1.3 and 1.2 pmol/mg of total protein (Fig. 2.9A). OCT 7 as well as OATP1B1 and 2B1 
were detected at within quantifiable limits in the HepaRG but not in HepG2 and Huh7. 
Among the efflux transporters MRP6 was the most abundant followed by MRP2, BSEP 
and MDR1. 
The disposition of phase I and II metabolizing enzymes in cHH, HLT and the 
hepatic cell lines is outlined in the Fig.2.7 and 2.8.  Human hepatocytes expressed all 
clinically relevant CYP450, such as, CYP1A2, 2B6, 2C9, 2C19, 2D6 and 3A4 at 1-24 
pmol/mg of total protein on an average, detected from the three lots of cHH. HepaRG cell 
line, expressed some of these enzymes in comparable levels, namely, CYP2C19, 2D6, 
3A4 and 3A5. In addition, CYP1A2, 2B6, 2C8 and 2C9 were detected at lower levels in 
HepaRG than cHH. In comparison, HepG2 cell line did not express CYP1A2, 2B6, 2C8, 
2C9, 2C19, 3A5 and 4A11 in detectable levels. In exception, to other CYPs, HepG2 cell 
line was a high expresser for CYP2C19 (32.6 pmol/mg of whole cell lysate). Likewise, it 
was interesting to note that Huh7 expressed CYP4A11, enzyme involved in fatty acid 
metabolism, at levels higher than human hepatocytes. Amongst phase II metabolizing 




similar levels in the cHH as seen in HepaRG cells. However, majority of the phase II 
enzymes detected in HepG2 and Huh7, were low abundance proteins (~1-2 pmol/mg of 
total protein) in comparison to cHH. 
3.5. Differentially regulated biological pathways in cell lines in comparison to human 
hepatocytes.  
      IPA predicted the top 5 dysregulated pathways from the protein expression in each 
group (HepaRG, HepG2, Huh7) vs. human hepatocytes with p value < 0.05 and log 
FC>0.58 or <-0.58 (Fig. 2.10). It was to be noted that the biological pathways that was 
perturbed was similar across the groups (Table 3.5). In addition, we also noted that the 
predicted top upstream regulator that was significantly inhibited across all cell lines, was 
found to be, HNF4α. We believe this probably contributes to the dysregulated protein 






4.  Discussion 
Human hepatic carcinoma cell lines are commonly used in drug development to aid safety 
assessment and for candidate selection for first-in-human (FIH) studies. Hence, there is a 
need for well-characterized, fit-to-purpose, proliferative hepatic cell lines models, due to 
the limited availability of primary human hepatocytes cells, inconsistency across donors 
and variability in DMET expression.24 In addition, the need to understand hepatic-disease 
state along with its impact on drug metabolizing enzymes propels the urgency for better 
preclinical models of human origin. With this objective in mind, we screened HepaRG cells 
as well as more traditional cell lines such as HepG2 and Huh7 for the expression of DME 
and proteins involved in energy and lipid metabolism.6,7 HepaRG are cells derived from a 
66 y old female patient with hepatocellular carcinoma.26 They are progenitor cells that 
upon differentiation exhibit 50% hepatocyte-like and/or 50% biliary-like cell lineages.27 In 
addition, upon differentiation, HepaRG cells are reported to express high levels of CYP450 
and other Phase I and Phase II enzymes, that is confirmed using several micro array 
studies.9,28,29 Apart from the reported gene expression data, very few reports discuss the 
global proteome of these cell lines as well as the targeted DME protein expression. Also, 
it is important to note that the known gene expression reports may not directly extrapolate 
to its protein expression or its activity.30 Proteins being the functional unit of most biological 
processes, it is critical to understand the protein expression profiles before choosing a 
hepatic cell line to model drug metabolism or disease state. 
To date, only a few proteomic studies have been reported in the literature 
comparing the global proteomes of hepatic cell lines and human hepatocytes as well as 
to quantify the DME protein expression. Some of the studies include contributions from: 
Slany et al. wherein the proteome profiles of primary human hepatocytes were compared 




proteomics31; Xiaomei Gu and colleagues compared the proteomic characteristics of 
HepG2, Hep3B2, H226, Ovcar3 and N87 using a TPA from Maxquant with DDA 
approach13; Sison-young et al. compared HepG2, Upcyte and HepaRG to primary human 
hepatocytes using a DDA strategy32; and recently Shi and colleagues used a DIA/SWATH 
based approach to compare HepG2, Hep3B, and Huh7 to human hepatocytes.14 In most 
cases, DDA based approach was used in analysis of proteomics signature. However, it 
has limitations for the quantification of low abundant proteins. In contrast, DIA based 
SWATH-MS approach is more sensitive and demonstrates high coverage, reproducibility 
and precision for low abundant proteins. Hence, DIA based SWATH-MS approach is ideal 
for measuring proteins in cell lines with low-to-moderate protein yield.  Using the SWATH-
MS detection method we compared the global proteome expression, along with targeted 
proteins involved in energy, lipid and xenobiotic metabolism among the cell lines and cHH 
as well as HLT. Moreover, in contrast, to all the above-mentioned literature that employed 
sub-cellular fractionation for enrichment, we analyzed the whole cell homogenate without 
fractionation, to prevent the loss of proteins associated with fractionation, as well as the 
variations associated with the scale-up of the fractionates. Henceforth, we believe, this 
analysis will result in higher reproducibility and limit the batch-to-batch variability 
associated with fractionation. 
In the current study, a spectral library was generated from the DDA scans. A total 
of <6000 proteins (combined) was identified using Protein Pilot at 1% FDR. However, not 
all proteins were detected in all replicates. DIA based total protein approach (DIA-TPA) 
was used to compare the global proteome among the different groups. We validated this 
approach by comparing the values of DMET proteins reported in literature as pmol/mg of 
total protein in wholes cell lysate. Wiśniewski et. al (2016) reported the protein levels from 




closely matched with the published literature, despite the different stratergy (DIA-TPA) 
involved in the analysis (Fig. 2.11-2.13). 
Similar to the previous reports, dramatically different global proteome profiles were 
observed between the cell lines and human hepatocytes (Figure 2.3, 2.4).14,32 However, 
hepatic carcinoma cell lines most closely related to each other in comparison cHH and 
HLT. Among the proteins expressed, the differentially regulated proteins as well as the 
perturbed pathways among the different groups were analyzed using IPA (Qiagen, 
Valencia, CA). As reported in the previous literature, the EIF2 signaling pathway, sirutin 
and MTOR pathway along with biological oxidation were significantly dysregulated in 
hepatic cell lines as opposed to human hepatocytes.14,32 
Several DMEs were quantified in the cHH and HLT as well as the cell lines using 
DIA based TPA approach. Among the 12 CYP450s quantified in cHH and HLT; 11 CYPs 
were identified in HepaRG; 7 CYPs in Huh7 and 5 CYPs in HepG2 cell line. The 
abundance of CYPs in HepaRG was more comparable to cHH than HepG2 and Huh7. 
UGTs were highly expressed in cHH and HLT. In HepaRG cell line, 10 UGTs and 2 SULTs 
were detected, however, UGTs (1A1, 1A3, 1A4 and 2B15) were not quantifiable in HepG2 
and HuH7. Hence caution must be taken while choosing these cell lines for drug 
metabolism related experiments. Having said that, it is also important to note that HepG2 
cells expressed high levels of, MGST2 (2-fold), POR (2.5-fold), DHRS2 (360-fold) in 
comparison to cHH. These enzymes have shown involvement in xenobiotic metabolism 
as well as cancer. In contrast, Huh7 cells expressed GSTP1 (75-fold), AKR1C1 (0.7-fold), 
ALDH1A1 (3-fold) and ADH5 (1.7 fold) in high abundance in comparison cHH (Appendix 
I). Therefore, these cell lines can be a legitimate in vitro model when experiments are 




With respect to the proteins involved in energy and lipid metabolism, we compared 
a proteins involved in glycolysis, ß-oxidation and lipogenesis across different groups. 
Majority of proteins involved in gluconeogenesis/glycolysis was expressed in high 
abundance in Huh7 cell line (Figure 2.4B). Interestingly, the average expression across 
the proteins involved in fatty acid metabolism was much higher in the HLT and cHH in 
comparison to cell lines. HepaRG, expressed a general lower trend than cHH followed by 
HepG2 and Huh7 cells. However, in contrast to the DME expression, the proteins involved 
in lipid metabolism was highly expressed in the carcinoma cell lines, but not of the similar 
abundance as human hepatocytes.  
In conclusion, in this publication we used a DIA based TPA strategy to compare 
proteome profiles of the whole cell homogenate of three hepatocarcinoma cell lines, i.e. 
HepG2, Huh7 and HepaRG and compared it with cHH and HLT in the focus of proteins 
associated to pathways of energy, lipid and xenobiotic metabolism. As discussed before, 
we observed significantly different protein expression profiles among the groups in energy 
and lipid metabolism as well as ADME protein expression. Therefore, caution must be 
exercised when choosing the cell lines as in vitro models for drug metabolism or 
developing models for disease states. This study provides a comprehensive database for 
understanding the expression of proteins in different cell lines and we believe it will aid in 









5. Figures and Tables 
 



































Figure 2.2: Venn diagram representing the overlapping number of proteins. 
The figure shows the identified number of proteins in (A) human livers tissue, human 
hepatocytes and the HepaRG, HepG2, and Huh7 cell lines and (B) HLT, Hepatocytes and 
HepaRG alone, quantified by SWATH-MS. All proteins were identified in all three 
replicates for each group. The diagram was produced using a web tool available at 



























Figure 2.3: Heirarchial clustering of proteins differentially expression.  
The figure (A) shows HLT, cHH, and the HepaRG, HepG2, and Huh7 cell lines (n= 3 for 
each group) clustered together depending on Euclidean distance matrix. The 30 most 
abundant proteins determined by DIA-TPA are represented in the heat map The MS2 
signal intensity was presented as a Log2 value. White spots indicate zero intensity. The 
figure (B) shows the grouping of cHLT, cHH and the HepaRG, HepG2, and Huh7 cell lines 
generated from SWATH-MS based data. 
Abbreviation: HLT – Human Liver Tissue; cHH – cryopreserved Human Hepatocytes; 
SWATH-MS - Sequential Window Acquisition of theoretical Mass Spectra; DIA-TPA – 
Data Independent Acquisition based Total Protein Approach. 
 















Figure 2.4: Correlation of protein abundances between the two groups. 
(A) Human Hepatocytes vs. HLT (B) Human Hepatocytes vs. HepaRG (C) Human 
Hepatocytes vs. HuH7 (D) Human Hepatocytes vs. HepG2. The global correlation in 
protein expression indicated in grey and the correlation of ADME proteins in black. Dotted 
lines indicate the line of unity. 












Figure 2.5: Heat map of the differential expression of protein involved in glucose 
metabolism using SWATH-MS. 
 The protein expression is represented as the log2 fold change between the test group 
(HLT, HepaRG, Huh7 and HepG2) vs. human hepatocytes. The figure shows proteins 
involved in gluconeogenesis/glycolysis. X – not applicable when protein expression is 







Figure 2.6: Heat map of the differential expression of protein involved in lipid 
metabolism using SWATH-MS.  
The protein expression is represented as the log2 fold change between the test group 
(HLT, HepaRG, Huh7 and HepG2) vs. human hepatocytes. The figure shows proteins 
involved in lipid metabolism. X – not applicable when protein expression is below limit of 







































































































Figure 2.7: Cytochrome P450 expressing profile from SWATH-MS.  
The significance was assessed using one-way ANOVA with multiple comparison 
Bonferroni test * denotes p <0.05; ** denotes p <0.01; *** p<0.001. ND stands for not 
determined due to low expression. The proteins were expressed as the average of 













































Figure 2.8: Drug metabolizing enzymes involved in phase II.  
The significance was assessed using one-way ANOVA with multiple comparison 
Bonferroni test * denotes p <0.05; ** denotes p <0.01; *** p<0.001. ND stands for not 
determined due to low expression. The proteins were expressed as the average of 
triplicates in pmol/mg of total protein. Error bars represent SD. Abbreviations: UGT - 




pmol/mg of cell homognate protein












































Figure 2.9: Xenobiotic transporters quantified using SWATH-MS.  
The significance was assessed using one-way ANOVA with multiple comparison 
Bonferroni test * denotes p <0.05; ** denotes p <0.01; *** p<0.001. ND stands for not 
determined due to low expression. The proteins were expressed as the average of 
triplicates in pmol/mg of total protein. (A) uptake transporters (B) efflux transporters. 







































































Figure 2. 10: Volcano plots representing number of differentially expressed proteins in HepaRG, HepG2 and Huh7 in 
comparison to Human Hepatocytes.  
Dots in blue represent the differentially expressed proteins based on FDR < 0.05 and log2FC <0.58 or log2FC >0.58 in (A) HepaRG 
(B) HepG2 (C) HepaRG in comparison to human hepatocytes. 
A B C 







Figure 2.11: Comparison of P450 protein using SWATH-MS DIA-TPA data with 
published data (Weisnewski et. al, 2016) based on DDA-TPA approach.  
The square in black represent the average of human hepatocytes (n=6) enzymes with min  
















Figure 2.12: Comparison of UGT proteins using SWATH-MS DIA-TPA data with 
published data (Weisnewski et. al, 2016) based on DDA-TPA approach.  
The square in black represent the average of human hepatocytes (n=6) enzymes with min 


















Figure 2.13: Comparison of transport proteins using SWATH-MS DIA-TPA data with 
published data (Weisnewski et. al, 2016) based on DDA-TPA approach.  
The square in black represent the average of human hepatocytes (n=6) enzymes with min  






















(years) Race Sex BMI 
M00995-P LQG 81% 8.98 32 WH M 23.5 
M00995-P AQL 91% 8.34 63 WH M 26.1 










 Table 2.2: Global hepatic protein in HepaRG, HepG2, Huh7 cell lines and human hepatocytes identified using Spectronaut 
 
 Human Hepatocytes Human Liver Tissue HepaRG HepG2 Huh7  





























































Proteins 2966 3028 3043 3335 3382 3,371 2904 3132 3057 2808 2967 2990 3249 3203 3088 
Proteins 
represente
d in all 
replicates 





Table 2.3: The proteins expressed in gluconeogenesis/glycolysis detected using SWATH-MS.  




Location Function cHH 














ALDOA Cytoplasm Gluconeogenesis/ Glycolytic process 1.2 5.2 15.0 40.5 25.4 
ENO1 Mitochondrion Cell membrane, cytoplasm and nucleus 13.6 60.8 87.1 145.2 55.2 
FBP1 Cytoplasm Gluconeogenesis 5.7 26.3 NA NA NA 
FBP2 Cytoplasm Gluconeogenesis 2.4 19.0 NA NA NA 






Glycolytic process 89.7 224.2 155.2 432.2 71.2 
GPI Cytoplasm Glycolysis 1.1 6.9 6.8 7.6 2.0 
HK1 Mitochondrion membrane protein Glycolysis 5.2 2.5 2.2 0.8 1.0 
LDHA Cytoplasm Pyruvate metabolism 38.0 204.8 175.8 351.6 122.3 
LDHB Cytoplasm Pyruvate metabolism 1.0 2.6 NA 0.6 NA 
PC Mitochondria Gluconeogenesis 20.7 14.6 3.2 2.7 3.0 
PCK1 Cytoplasm Gluconeogenesis 1.8 2.8 16.9 NA 0.3 
PCK2 Mitochondria Gluconeogenesis 84.5 21.5 13.8 3.3 17.7 
PFKL Cytoplasm Glycolysis 0.7 1.5 0.4 1.5 0.5 
PGAM1 Nucleus Glycolysis 4.3 20.8 13.4 43.3 5.7 





PKLR Cytosol Glycolysis 4.2 6.9 32.0 80.9 12.0 
PKM Nucleus Glycolysis 1.6 2.3 72.9 173.7 22.8 





  Table 2.4: The proteins expressed in lipid metabolism detected using SWATH-MS.  
  The average of the triplicates is tabulated and expressed in pmol/mg of protein. NA - Protein expression below detectable limits. 
Gene 
Name 


















ER and mitochondria Acyl-CoA Ligase 38.2 35.3 27.6 0.4 1.0 
ACSL3 
Peroxisome,  
ER and mitochondria Acyl-CoA Ligase 0.8 1.8 3.4 6.1 11.1 
ACSL5 
Peroxisome,  
ER and mitochondria Acyl-CoA Ligase 7.7 6.5 6.3 3.9 15.3 
ACAA1 Peroxisome Peroxisomal !-oxidation  47.2 24.5 15.3 9.6 4.4 
ACOX1 Peroxisome Peroxisomal !-oxidation  3.2 1.9 1.6 1.2 1.5 
ACOX2 Peroxisome Peroxisomal !-oxidation  7.4 3.5 0.8 0.9 0.8 
ACOX3 Peroxisome Peroxisomal !-oxidation  0.7 0.6 0.7 0.4 0.3 
EHHADH Peroxisome Peroxisomal !-oxidation  17.1 10.8 8.5 0.6 0.8 
HSD17B4 Peroxisome Peroxisomal !-oxidation  57.7 42.6 34.8 10.6 12.9 
CPT1A Mitochondria Carnitine Shuttle 1.6 1.4 1.6 0.5 2.3 
CPT2 Mitochondria Carnitine Shuttle 6.6 6.6 4.5 1.5 1.5 
SLC25A20 Mitochondria Carnitine Shuttle 9.8 4.9 4.4 2.0 1.6 
ACAA2 Mitochondria Mitochondrial !-oxidation  125.6 79.3 30.7 7.2 7.8 
ACADL Mitochondria Mitochondrial !-oxidation  1.0 0.4 1.5 NA NA 
ACADM Mitochondria Mitochondrial !-oxidation  28.3 20.4 13.5 2.8 5.3 
ACADS Mitochondria Mitochondrial !-oxidation  16.1 13.4 0.9 1.0 2.2 
ACADSB Mitochondria Mitochondrial !-oxidation  20.6 12.4 2.8 2.1 9.9 
ACADVL Mitochondria Mitochondrial !-oxidation  9.8 10.9 10.7 3.2 2.8 
ECHDC1 Mitochondria Mitochondrial !-oxidation  1.4 2.6 1.9 0.9 1.4 





ECHDC3 Mitochondria Mitochondrial !-oxidation  8.5 3.8 9.3 0.8 NA 
ECHS1 Mitochondria Mitochondrial !-oxidation  181.5 110.4 35.2 17.9 13.5 
HADH Mitochondria Mitochondrial !-oxidation  48.6 40.4 23.1 5.2 9.5 
HADHA Mitochondria Mitochondrial !-oxidation  28.4 23.4 20.4 6.9 17.6 
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Background & Aims. Hepatic lipid accumulation (steatosis) is an early sign of a spectrum 
of Non-alcoholic Fatty Liver Disease (NAFLD) that precedes fibrosis and cirrhosis.  To 
manage NAFLD and related co-morbidities, patients are administered an array of 
pharmacological agents.  Therefore, understanding of the effect of NAFLD on drug 
disposition is warranted.  Using a HepaRG model, we aimed to mimic steatosis in vitro, 
and to examine its effects on drug-metabolizing enzymes (DME) and transporters. 
Methods. HepaRG cells, differentiated in-house, were exposed to a mixture of saturated 
and unsaturated fatty acids (1:2 ratio of 0.5 mM palmitate and oleate complex conjugated 
to BSA for 72h) and were subjected to RNA sequencing and proteomic analyses.  Lipid 
accumulation was ascertained by Oil Red O (ORO) staining and triglyceride (TG) 
quantitation and cell viability by WST-1 determination. 
Results. The treatment condition resulted in ~6-fold increase in TG concentration without 
reducing cell viability.  RNA sequencing and Proteomics (SWATH-MS) of lipid-loaded and 
control cells identified a total of 393 differentially expressed transcripts (89 up- and 304 
down-regulated) and 127 differentially expressed proteins (127 up- and 38 
downregulated), respectively.  Moreover, lipid loading resulted in significant down-
regulation of mRNA transcripts of transcription factors, NR1I2 (-1.18) and HNF4α (-0.55), 
phase 1 DMEs including CYP1A2 (-3.25), 2B6 (-2.02), 2C8 (-1.48), 2C9 (-2.00),2C19 (-
1.32) and 3A4 (-1.87), phase 2 DMEs including UGT1A6 (-0.36) and 2B7 (-1.09), 
SULT2A1 (-0.75) and 1E1 (-1.41) as well as clinically relevant transporters such as 
ABCC11 (-1.36), ABCG5 (-1.66), SLC10A1(-1.63), SLCO2B1(-1.49) and SLC10A1 (-
1.63).  Furthermore, lipid loaded cells significantly upregulated AKR1B10 mRNA (2.17) 




Conclusion.   Expression of several DME and transporter mRNA was altered in an in vitro 
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Nonalcoholic fatty liver disease (NAFLD) is highly prevalent in the United States as 
well as other developed counties (Bellentani, 2017).  Excess intake of calories and lack of 
physical activity can cause accumulation of free fatty acids (FAF) and triglyceride (TG) in 
hepatocytes leading to the development of steatosis (Veteläinen et al., 2007).  NAFLD 
which is associated with metabolic syndrome, includes a spectrum of liver disorders, 
initiating with simple steatosis, progressing to nonalcoholic steatohepatitis (NASH) and 
possibly lead to end-stage cirrhosis (Koo, 2013; Cobbina and Akhlaghi, 2017). 
Furthermore, patients with steatosis are at a greater risk of developing hepatocellular 
carcinoma (HCC) (Ohata et al., 2003).  The benign nature of steatosis is considered as 
the "first hit" in the progression of NAFLD.  The "second-hit" is manifested via reactive 
oxygen species (ROS) induced stress, which leads to the infiltration of inflammatory 
factors, hepatocellular ballooning and deposition of collagen fibers in hepatocytes as 
observed in NASH and fibrosis (Caldwell and Argo, 2010).   
Approximately 29% of the patients diagnosed with NASH will develop cirrhosis later in 
life (Cohen, Horton and Hobbs, 2011).  Currently, many pharmaceutical companies are 
aspiring to develop medications for the treatment of NAFLD (Noureddin, Zhang and 
Loomba, 2016; Brodosi et al., 2016). Moreover, considering that NAFLD is associated with 
other co-morbidities including diabetes (Brunt and Tiniakos, 2010), patients are 
administered several other medications and are at a greater risk of adverse drug reactions. 
Recently, it was shown that the ADME (Absorption, Distribution, Metabolism and 
Excretion) properties of midazolam and morphine is altered in NAFLD or NASH (Jamwal 
et al., 2018; Farrow and Facchini, 2013). Hence, a comprehensive understanding of the 
differential expression of Drug-Metabolizing Enzyme and Transporters (DMET) in NAFLD 




To study steatosis, it is crucial to identify an appropriate disease model. Significant 
differences exist in the manifestation of this disease between humans and rodents.  Diet-
induced mouse models fail to recapitulate the full spectrum of NAFLD manifestation in 
human (Gómez-Lechón, Jover and Donato, 2009; Merrell and Cherrington, 2011).  
Feeding high-fat diet (HFD) to mice generate simple steatosis; however, male C57BL/6 
mice fail to progress to NASH even in the presence of a high fructose-rich diet (Takahashi, 
Soejima and Fukusato, 2012). Whereas, a methionine-choline-deficient (MCD) diet 
induces a phenotype of severe NASH without metabolic syndrome and obesity features 
16.  In addition, genetically modified mouse models including ob/ob or db/db often fail to 
recapitulate the full spectrum of the disease (Larter and Yeh, 2008).  Collectively, the 
disparity between rodent models and human with respect to the regulation and tissue 
distribution of DMETs (Prueksaritanont, 2010) (Martignoni, Groothuis and de Kanter, 
2006) limit the usefulness of data obtained from animal models of NAFLD/NASH.   
Use of primary human hepatocytes (PHH) or cryopreserved hepatocytes is considered 
the gold standard for studying DMET in vitro (Lecluyse and Alexandre, 2010).  In addition, 
FA-loading has been previously attempted with primary human and rat hepatocytes using 
static and dynamic chip-based systems (Donato et al., 2006; Kostrzewski et al., 2017; 
Bulutoglu et al., 2019). However, the availability of early-stage biopsy samples, donor-to-
donor variability, cost involved in model development and limited time in culture before the 
onset of dedifferentiation diminishes the utility of PHH as an effective tool for disease 
model development.  In this regard, the HepaRG cell line is a promising in vitro model 
presenting a more robust DMET gene expression pattern than HepG2 and Huh7 cell lines 
(Gerets et al., 2012).  HepaRG cells are an immortalized human hepatocellular carcinoma 
cell line comprised of a mixture of both hepatocyte-like and biliary-like cells (Guillouzo et 




differentiation (Aninat et al., 2006).  These attributes make HepaRG cells a suitable cell 
line for the development of a disease model and its utilization for studying therapeutic 
modalities. 
We aim to characterize the molecular basis of NAFLD using a HepaRG model aiming 
to understand the regulation of DMET in the disease state.  Steatosis was induced by 
treating HepaRG cells with a mixture of saturated and unsaturated fatty acids (FA).  To 
obtain steatotic global gene expression profiles, we carried out RNA sequencing (RNA-
Seq) on HepaRG cells treated with FA or control.  Subsequently, the proteomics signature, 






2. Material and Methods 
2.1 Cell Culture Model 
HepaRG cells were purchased from Biopredic International (through licensing 
agreement from Inserm, France) and were grown and differentiated in-house according to 
manufacturer's instructions.  The incubation was carried out in a at 37 °C with 5% CO2 
(New Brunswick Galaxy® incubator CO2, Model# 170R, New Brunswick, NJ).  Following 
14 days growth and 14 days differentiation phases, the cells were seeded in a 24 well 
plate, and were treated with basal medium containing Williams E with Glutamax-I, 100 
IU/ml of penicillin, 100 μg/ml of streptomycin, 4 μg/ml of bovine insulin and 5 × 10−5 M of 
hydrocortisone hemisuccinate for 5 days. 
To induce steatosis, HepaRG cells were treated with FA (1:2 palmitate: oleate) 
conjugated to 30% essentially fatty acid-free (FAF) BSA solution (Sigma-Aldrich, Catalog# 
A9576, Saint Louis, MO) made up in Williams E media (Thermo-Fisher Scientific, Catalog# 
12551-032, Waltham, MA).  The control cells were treated with 30% essentially FAF BSA 
solution alone.  The cells were treated for 24h, 48h and 72h with media replenished after 
48h (Brown et al., 2013). 
2.2 Oil Red O Staining 
HepaRG cells treated with 0.5 mM FA or control for 24h, 48h and 72h.  Cells were 
washed twice with 1X PBS and fixed with 4% paraformaldehyde (Sigma-Aldrich, Catalog# 
100496, Saint Louis, MO) for 30 min in room temperature (RT).  Following this, 500 µl of 
working Oil Red O (ORO) solution (3 parts of stock ORO and 2 parts of dH2O) (Sigma-
Aldrich, Catalog# O0625, Saint Louis, MO) was added and incubated at RT for 20 min.  
The cells were washed 3X with distilled water (dH2O), and 500 µL of hematoxylin (Sigma-
Aldrich, Catalog# H3136, Saint Louis, MO) was added for 1 min to stain the nuclei and 




M7000, Foster City, CA).  The extent of neutral lipid accumulation was quantified after 
extraction in 100% isopropanol, and the absorbance was measured at 492 nm using a 
SpectraMax plate reader (Molecular Devices, Model# M2, Sunnyvale, CA). 
2.3 WST-1 cell viability  
Cells were treated with 0.1-2 mM BSA conjugated with FA (1:2 palmitate: oleate) 
for 72h in a 96 well format.  The positive control used for this experiment was clotrimazole 
(100 µM).  Following treatment, WST-1 reagent (Roche Diagnostics, Catalog# 
11644807001, Mannheim, Germany) was diluted 100X times in HepaRG basal media.  
The media was added to cells and incubated in 37 °C for 4h.  The supernatant was 
collected and analyzed using the SpectraMax M2 plate reader at 440 and 600 nm 
wavelengths. 
2.4 TG Accumulation 
Approximately 10 million cells (HepaRG control vs. FA) were rinsed with PBS and 
scraped off the flask using a rubber policeman cell scraper.  Cells were resuspended in 
PBS and lysed by sonication twenty times with one-second bursts.  The samples were 
centrifuged at 10,000 xg for 10 minutes at 4 °C, and the supernatant was collected and 
assayed for TG content using a TG colorimetric assay kit (Cayman Chemicals, Catalog# 
10010303, Ann Arbor, MI) according to manufacturer's protocol.  The optical density was 
read at 540nm on SpectraMax M2 plate reader. 
2.5 Cholesterol Assay 
One million HepaRG cells (0.5 mM FA treatment vs. control) were trypsinized, and 
cell pellets were lysed with 200 μL of chloroform: isopropanol: NP-40 (7:11:0.1) in a micro-
homogenizer. The cell lysate was centrifuged at 15,000 x g for 10 min. The supernatant 
was isolated and air dried at 50 °C to remove the chloroform.  Samples were placed in a 




mixed in 200 μL of 1X assay diluent with sonication and vortex mixed until dissolved.  The 
extracted samples were assayed using a total cholesterol calorimetric assay kit (Cell 
Biolabs Inc., Catalog# STA-384, San Diego, CA). 
2.6 Assessment of Oxidative Stress  
Differentiated HepaRG cells (10 million cells) were treated with BSA or FA 
treatment (0.5 mM) for 72 hours in triplicates.  Oxidative stress was analyzed as a measure 
of lipid peroxidation to Malondialdehyde (MDA).  The samples were quantified using 
OxiSelect™ TBARS Assay Kit (Cell Biolabs Inc., Catalog# STA-330, San Diego, CA).  
Following this, samples were analyzed at 542 nm using SpectraMax M2 plate reader.   
2.7 Insulin-stimulated phosphorylation of Protein Kinase B (Akt)  
Following 72h of FA treatment, HepaRG cells were placed in serum-free EMEM 
media for 12 h followed by stimulation with recombinant human insulin (Sigma-Aldrich, 
Catalog# 1376497001, Saint Louis, MO) at 1, 10 or 100 nM for 10 min at 37 °C.  Samples 
were rinsed in PBS and lysed with RIPA buffer (150mM NaCl, 50mM Tris, 1% NP-40, 
0.5% sodium deoxycholate, 0.1% SDS, 1mM EDTA) supplemented with a complete 
protease inhibitor cocktail (Sigma-Aldrich, Catalog# CO-RO, Saint Louis, MO) and Halt 
Protease Inhibitor Cocktail (Thermo Fisher Scientific, Catalog# 78430, Waltham, MA) for 
30 min at 4 °C.  The lysate was run on a sandwich ELISA kit that detects both pAkt 
(Ser473) and total Akt (Abcam, Catalog#126433, Cambridge, MA).  The assay was 
performed according to manufacturer's protocol and the results were expressed as a ratio 
of phospho-Akt to total Akt. 
2.8 RNA extraction and sequencing 
Total RNA was extracted using RNeasy Mini Kit (Qiagen, Valencia, CA) from 
differentiated HepaRG cells (1 million cells per well) plated in a 6-well plate (0.5 mM FA 




for RNA extraction and subsequent sequencing. The ratio of absorbance at 260 nm and 
280 nm was used to assess the purity of RNA using Nanodrop (Thermo Fisher Scientific, 
Catalog #ND-ONE-W, Waltham, MA).  Samples with a 260/280 ratio of ~1.8 and RNA 
Integrity Number (RIN) > 8 were selected for further analysis.  RNA integrity and quantity 
were measured using Agilent 2100 Bioanalyzer System (Agilent Technologies, Santa 
Clara, CA).  Total RNA input for library preparation was assessed using the Qubit RNA 
BR assay (ThermoFisher Scientific catalog# Q10210). RNA sequencing was performed 
on 100ng of oligo(dT) purified poly(A)+ mRNA. A standard TruSeq mRNA library was 
constructed using TruSeq® Stranded mRNA NeoPrep™ Kit v2 (Illumina, Catalog # NP-
202-1001, San Diego, CA). The library was sequenced by Illumina NextSeq 500 using a 
paired-end run (2×75 bases).   The fastq files were generated using BaseSpace via 
bcl2fastq.  
2.9 RNA-seq data analysis 
Sequencing data have been uploaded in the Gene Expression Omnibus (GEO) database 
that can be viewed with the accession number of GSE122151. The data analysis and 
visualization were carried out using QuickRNASeq, an integrated pipeline used in the 
analysis for large-scale RNA-Seq data (Zhao et al., 2016). Read mapping and counting 
was performed using STAR and featureCounts.  Following this, RSeQC package was 
included to employ all the QC metrics and to remove outliers; whereas VarScan, platform-
independent software tool was included for variant detection in RNA-Seq data.  A 
generalized linear model was used instead of a pairwise comparison approach to account 
for the changes between treatment and control according to the R user’s guide to 
determine differentially expressed genes.  We used log2 FC > 0.58 as a cut-off combined 
with exclusion criteria with False Discovery Rate (FDR) < 0.01 and p-value < 0.05, to 




2.10 SWATH-MS acquisition and data analysis  
Cell homogenate samples were analyzed using SWATH-MS based spectra which 
were acquired for mass range m/z 400−1100 Da within SWATH window width of 10 m/z 
resulting in 70 overlapping mass windows per cycle, as described in the previous literature 
(Jamwal et al., 2017). The DIA data was searched against Swiss-Prot identifiers (October 
2016) and analyzed using Spectronaut™ Pulsar software (version 11.0, Biognosys AG, 
Schlieren, Switzerland) was used to obtain MS2 signal intensities of fragment ions from 
DIA data using default settings with a few modifications that includes specific trypsin/P 
digestion with a minimum of 7 amino acids, maximum of 52 amino acids and 2 missed 
cleavages; fixed modifications included carbamidomethyl (C) and variable modifications 
included acetyl (protein N-terminus) and oxidation (M). Raw data files and search results 
are available at Japan Proteome Standard Repository (jPOSTrepo JPST000372, 
ProteomeXchange PXD008593). The SWATH-MS DIA data was matched with the 
reference spectral library generated from the DDA of pooled human liver samples using 
Protein Pilot. The DIA data was then normalized and analyzed using “Total protein 
approach” (TPA), as shown below (1).  
          …(1) 
The absolute protein abundance of each group was represented as pmol/mg of protein. 
2.11 Gene Expression Validation 
Real-Time PCR.  Real-time PCR for human CYP mRNA levels was performed using a 
ViiA7 Instrument (Thermo Fisher Scientific, Catalog # 4453534, Waltham, MA) and 
TaqMan assays used are as follows: CYP3A4 (Hs00604506_m1); CYP2E1 




(Hs99999905_m1); 18 S (4332641); and β-actin (Hs99999903) (Thermo Fisher Scientific, 
Waltham, MA). GAPDH, 18 S rRNA and β-actin were used as housekeeping gene controls 
to normalize the data. The reaction mixture (20 μl/well) contained 30 ng of cDNA (2 μl), 
10× Taqman Universal Master Mix (10 μl), Taqman primers (1 μl) and RNase free water 
(7 μl). The thermal cycle conditions were identical for all the genes analyzed. The qPCR 
steps include 50 °C for 2 min followed by denaturation at 95 °C for 10 min, 40 cycles of 
95 °C for 15 s and 60 °C for 1 min.  Fold change was calculated by the formula: Fold = 
2−ΔΔCt, where ΔCt represents the difference in cycle threshold number between the target 
gene and the housekeeping gene, whereas ΔΔCt represents the difference between 
control and fatty acid treatment groups.  mRNA samples from individual wells treated with 
FA treatment or control conditions were analyzed in triplicate, and data were analyzed 
using Data Assist software (Thermo Fisher Scientific, v3.01, Waltham, MA). 
2.12  Characterization of Enzyme Activity 
HepaRG cells grown on twenty-four-well plates of were used for activity 
measurements.  After 72 h in culture, treatment media was removed, and the cells were 
washed twice with 1xPBS; after that, 230 μL of medium was added to each well.  The 
medium consisted of Williams' medium E containing different concentrations of CYP 3A4 
substrate, midazolam (0.1, 0.5, 1, 3, 10, 30 μM) (TRC, Catalog# KIT0040, North York, ON, 
Canada) or CYP2E1 substrate, chlorzoxazone (500, 750, 1000 μM) (TRC, Catalog# 
C428700, North York, ON, Canada), and incubated for 1h or 8h respectively.  The 
compounds were dissolved in DMSO and then added to the media.  The final 
concentration of DMSO was maintained at 0.1%, and samples were analyzed in triplicates.  
The reaction was quenched by equal volume of the internal standard containing ice-cold 
acetonitrile and 0.1% formic acid.  The samples were analyzed for the CYP3A4 metabolite 




H825120 North York, ON, Canada). [2H4] hydroxymidazolam (Catalog# H948423) and 
[2H2] hydroxychlorzoxazone (TRC, Catalog# H825123 North York, ON, Canada) were 
used as internal standards respectively. 
The mass spectrometry parameters were optimized for each analyte (Dostalek et 
al., 2010).  The multiple reaction monitoring transitions chosen were m/z 342 → 203 for 
1-hydroxymidazolam and m/z 346 → 203 for d4-hydroxymidazolam. The assay was linear 
from 1 to 25 ng/mL (R2 > 0.99). The transition chosen for hydroxychlorzoxazone was m/z 
183.8 → 119.8 and for d2 hydroxychlorzoxaxone was m/z 187.6 → 121.9. This assay also 
showed linearity 9 to 925 ng/mL (R2 > 0.95) and precision. 
2.13 Data and statistical analyses 
RNA-Seq data were analyzed using IPA (Ingenuity Pathway Analysis) software for 
studying the disease and other canonical pathways, utilizing the generalized pathways 
that represent common properties of a signaling module using the KEGG database 
(Qiagen, Foster City, CA).  Differential gene expression of FA treated cells was normalized 
to the control and reported as log2 of the fold change (log2FC). HemI (Heatmap Illustrator, 
version 1.0) was used to generate the heatmap of differentially expressed genes. In most 
cases, data were averaged for each experiment performed as triplicates and data were 
presented as mean ± SEM relative to BSA for each condition. Unpaired Student's t-test 
analyzed column statistics between control and FA treated groups. Data were analyzed, 





3.1 Development of the steatosis model with HepaRG cell line  
Upon treatment, the neutral lipid accumulation was visualized at 24h, 48h and 72h 
utilizing ORO stain (Fig 3.2-I).  There was an increasing trend in the lipid accumulation, 
with 72 h post-treatment showing (Fig 3.2-II) the highest accumulation of lipids.  To further 
define the treatment concentration, varying range of FA (0.1 - 2.0 mM) at 72 h, were 
assessed for changes in the cell viability.  As shown in Fig 3.2-III, 0.5 mM of FA treatment, 
did not induce any detectable toxicity to the cells and hence was used for further 
characterization. 
3.2 Validation of FA treated HepaRG cells as a model for steatosis 
Increased total TG and cholesterol levels were observed under FA treatment 
conditions. There was a 6-fold increase in triglyceride levels in FA treatment vs. control 
(Fig. 3.3A).  Cholesterol concentration showed ~1.3-fold increase in the FA treatment 
group compared to control (Fig. 3.3B).  To assess the effect of FA treatment on 
hepatocellular oxidative stress, the mean level of malondialdehyde (MDA) was measured 
(Fig. 3.3C).  However, there was no significant difference between the FA treatment and 
control cells.  This observation suggests that FA treatment may not induce oxidative 
stress. 
Insulin signaling, which is often hindered in steatosis, was assessed in FA treated 
HepaRG cells.  Total Akt levels remained constant for all treatment conditions.  At every 
concentration increment of insulin, a significant reduction in the levels of phospho-Akt was 
noted within the FA treatment group as compared with control (Fig. 3.3D).  This finding 




In addition, we compared the transcriptomics data with a clinical study (Starmann 
et al., 2012) that reported the hepatic gene expression difference between liver steatosis 
(n=30) and control (n=18). Of the top 100 differentially expressed genes, 24 genes 
overlapped with our dataset and are summarized in Table 3.1. The genes ACSL4/5, CAT, 
PNPLA3, ATF3, GSTM5, and NR0B2, were previously reported (Stepanova et al., 2010; 
Younossi et al., 2005) to show a positive correlation with NAFLD.  
3.3 Pathway analysis of differentially regulated genes upon FA treatment vs. control 
IPA was used to identify significant pathways affected by differential regulation of 
genes from FA treatment of HepaRG cells.  To further examine the model, we used the 
differentially expressed (DE) genes to predict the disease state.  Two hundred seventy-
nine canonical pathways were significantly altered in the dataset of 393 DE genes (Fig. 
3.4A). The top twenty pathways are listed in Table 3.2.  It is important to interpret this 
information with caution as the dysregulated canonical pathways were mostly represented 
by a small fraction of differentially regulated genes (less than 20), in such cases the 
pathway was not considered significantly dysregulated.  Amongst the enriched pathways, 
the pathways that were dysregulated upon FA treatment, include FXR/RXR, LXR/RXR 
activation, LPS/IL-1 mediated inhibition of RXR, xenobiotic metabolism, coagulation 
system and acute phase response signaling (Fig. 3.4C).  Differentially expressed genes 
were also grouped to predict the disease state with the IPA software (Table 3.3).  It is 
interesting to note the top-scoring and statistically significant (p<0.05) predictions in the 
category of metabolic diseases was that of hepatic steatosis, microvesicular steatosis, 
non-alcoholic fatty liver disease and steatohepatitis (Fig. 3.4B). 




Similar to the gene expression pattern that predicted hepatosteatosis (Fig. 3.4C), 
significant changes in protein expression that was associated with hepatocellular injury 
was observed with fatty acid accumulation. Addition of fatty acids induced the proteins 
PGK1, ALDOA, PGAM1 involved in glycolytic pathways as seen in steatosis, that leads to 
the formation of glycerol which is the key component in TG formation (Fig. 3.5A). In 
addition, we noticed a decrease in albumin production and increase in ALT production as 
seen in hepatocellular injury (Fig. 3.5B). Moreover, increased protein expression of 
collagen (COL18A1) and TNF-α are indicators of early stage progression to NASH. 
3.5 Effect of FA treatment on immune response as well as lipid catabolism, lipid synthesis 
and transport 
FA treatment significantly upregulated the transcription of genes involved in 
inflammation (Moylan et al., 2014), FA metabolism as well as some DMET mRNA which 
are represented in Fig. 3.5B.  Genes are known to be involved in inflammation and immune 
response, including, PDK4 (1.54), CD36 (1.38), CD74 (1.02), TNFAIP6 (2.04), PTGFR 
(0.73) and IL6 (1.28) were upregulated. This data was positively correlated with the 
induction of protein expression PDK4 (2.44), CD36 (2.11) and TNFAIP6 (1.08) (data not 
shown). Additionally, mRNA and protein associated with FA oxidation such as ACSL1, 
ACSL4, ACOT, ACOX4 were observed to be upregulated.  In addition, we also observed 
increased expression mRNA and protein associated with denovo-lipogenesis ACACB, 
PLIN2, PLIN4 and SCD.  In addition, we noticed increased protein expression of CD36 
and FABP4 contributing to the increased influx of FA in the hepatocyte-like cells. 
Collectively, these results support the idea that FA accumulation in HepaRG cells exhibits 
broad regulatory roles on immune response, lipogenesis, lipid catabolism and transport.  




We compared the transcriptomes between FA treatment and control HepaRG cells 
and identified significant changes in genes, suggesting the role of FA accumulation as an 
initial trigger to the onset of hepatosteatosis (Fig. 3.4C).  Furthermore, FA treatment 
resulted in differential mRNA expression of the phase I (17 different CYP isoforms, 4 
different ADH isoforms and FMO5), phase II (2 different GST isoforms, 7 different UGT 
isoforms, 2 isoforms of SULT), transporter (5 different ABC superfamily, 3 of SLC 
superfamily) (Fig. 3.7A).  Treatment with FA for 72h shows a statistically significant 
(p<0.05) downregulation of some CYP isoforms, namely, CYP3A4, 1A2, 2B6, 2C8, 2C9 
and 2C19 with log fold change in the order of -1.87, -3.25, -2.02, -1.48, -2.00 and -1.32 
respectively (Table 3.2).  Along with this UGT1A9 (-1.39), UGT1A6 (-0.36), SLCO2B1 (-
1.49). In terms of the observed protein expression (Fig. 3.7) we noticed a lower trend in 
CYP2A6, CYP2C8, CYP2C9 and CYP3A5 as well as UGT2A3 and UGT2B7, however, 
the results were not statistically significant.  
Moreover, the expression pattern of nuclear receptors ad transcriptional factors 
was further investigated. mRNA expression of NR1I2 (-1.18), NR1I3 (-1.96), PPARα (-
0.24) and HNF4α (-0.55) were significantly downregulated (Figure 3.7B). In agreement 
with the RNA-Seq data, qRT-PCR results indicated that expression of the nuclear 
receptors PXR (NR1I2) and CAR (NR1I3) and CYP3A4 was markedly reduced upon FA 
treatment (Fig. 3.7C). Furthermore, mRNA and protein of transcriptional regulator, 
AKR1B10 was positively increased. This suggests that FA accumulation in steatosis 
induce AKR1B10 that may modulate the lipid metabolism as well as basal expression of 
drug-metabolizing enzymes (DMEs) in hepatocytes.   
3.7 Functional activity of CYP3A4 in control and fatty acid treatment 
CYP3A4, the most abundant human hepatic CYP (Saravanakumar et al., 2019) , 




activity in FA-treated HepaRG was assessed using midazolam as a substrate. Upon FA 
treatment, the CYP3A4 enzyme activity was significantly reduced.  FA-treatment resulted 
in a 10-fold reduction in CYP3A4 (maximal rate of metabolism, Vmax) activity compared 
to the control at 10 µM (Fig. 3.8B). Both our RNA-seq, PCR data as well as enzyme activity 
showed marked downregulation in CYPs and its corresponding nuclear receptors, 
demonstrating the link between lipid metabolism in steatosis cells with that of xenobiotic 






We have established an in-vitro model for hepatic steatosis and validated this 
model by various approaches.  Utilizing transcriptomic analyses, we have examined 
altered molecular signaling pathways upon FA accumulation in HepaRG cells.  In addition, 
we collaborated this with proteomics analysis. Our data agree with earlier reports 
describing the response to FA loading on lipogenesis as well as inflammatory modulators 
(Rubin et al., 2015; Parafati et al., 2018). 
Hepatic steatosis is characterized by increased accumulation of neutral lipids and 
TG in intracytoplasmic micro/macrovesicles triggered by multiple factors especially in the 
presence of FA (Gómez-Lechón, Jover and Donato, 2009).  Presence of lipid droplets and 
increased TG accumulation has been previously reported for in vitro cultures in the 
presence of long-term stimuli with (unsaturated) oleic acid (Antherieu et al., 2011; Rogue 
et al., 2014) and short-term treatment with a mixture of oleate and palmitate (O/P) (Dave, 
Tilles and Vemula, 2018; Chavez-Tapia, Rosso and Tiribelli, 2012; Brown et al., 2013).  
The investigations on hepatic lipid content in NAFLD and NASH patients reveals increased 
levels of O/P and a trend that shows a shift towards O/P with the disease progression 
(Araya et al., 2004).  Hence, it was physiologically relevant to treat the HepaRG cells with 
O/P to stimulate steatosis.  Moreover, we used a 2:1 ratio of O/P to mitigate the lipotoxic 
effects of palmitate treatment (Montell et al., 2001; Wei, Wang and Pagliassotti, 2007).  
Here we report a 6-fold increase in TG content as well as increased lipid-filled vesicles in 
HepaRG cells after a 72h stimulus with 0.5mM of O/P (2:1).  This in vitro model also 
showed a positive correlation with several genes associated with de-novo lipogenesis 





HepaRG cells treated with 0.5 mM O/P (2:1) showed a significant downregulation 
of PXR, CAR, and PPARα as well as the target CYP mRNA.  Our results is in agreement 
with previous reports showing downregulation of PPARα in hepatic steatosis (Pawlak, 
Lefebvre and Staels, 2015).  However, in contrast to our observations, Tanner et al. 
reported no change in mRNA of DMETs as well as the nuclear receptors such as PXR, 
CAR, and PPARα upon treatment with O/P (Tanner et al., 2018).  However, the FA 
treatment method was different from our experiment including the proportion of the two 
FA (1:1 O/P vs. 2:1 O/P), incubation period (24h vs. 72h) and concentration of FA 
treatment (125 µM vs. 500 µM), which might explain the discrepancies between the two 
studies. 
 Previous studies have reported the impact of hepatic steatosis on P450 enzymes 
and cell membrane transporters (Lake et al., 2011; Fisher et al., 2009; Hardwick et al., 
2013). In our NAFLD model, the gene expression of CYP including CYP3A4, 1A2, 2B6, 
2C8, 2C9, 2C19 and 4A11 were significantly reduced. Additionally, we also observed a 
lower trend in CYP2A6, CYP2C8, CYP2C9 and CYP3A5 protein expression, however this 
was not statistically significant findings. Similar changes in gene expression were 
previously observed by Donato et al. (Donato et al., 2006) using plated human 
hepatocytes, but these were only exposed to FFA for 14 h and the impact on other ADME 
proteins were not extensively explored. Kostrzewski et al. (Kostrzewski et al., 2017), 
reported using a 3D human hepatocytes model of NAFLD that the metabolic rates of 
CYP3A4 and CYP2C9 to be reduced, with no changes in the genomic expression. These 
contrasted with our findings that show significant mRNA change, as our model is specific 
to early stages of steatosis that reverts during disease progression. In summary, utilizing 
an in vitro model of liver steatosis, our data demonstrate broad alterations in ADME, upon 




Increased infiltration of the FA in the liver results in an alteration in β-oxidation via 
TCA cycle and increased TG synthesis to compensate with the overload, that eventually 
leads to hepatocyte enlargement (Diraison, Moulin and Beylot, 2003).  This transition is 
reflected in HepaRG FA treatment with the upregulation of aldo–keto reductase (AKR) 
1B10 which regulates acetyl-CoA carboxylase (ACC)-catalyzed reaction step of de novo 
lipogenesis (Bitter et al., 2015).  Upregulation of PLIN2 is also noted, which coats lipid 
droplets and prevents TG to undergo lipolysis via LPL.  Downregulation of PPARα which 
is important in lipid metabolism and regulates the expression of PLIN2 is noteworthy and 
consistent with the literature (McManaman et al., 2013).   
High-sensitivity C-reactive protein is a clinical predictor of NAFLD (Fierbinteanu-
Braticevici et al., 2011); in the current study, this marker was upregulated along with a 
minimal increase in serum amyloid A2 and IL-6 (Table 3.4).  However, induction of acute-
phase proteins upon FA treatment shows the early signs of progression from steatosis to 
the development of NASH.  Despite the induction of a few inflammatory markers, there is 
no evidence to show the presence of oxidative stress in the cells, and hence this model is 
more representative of hepatic steatosis and co-culture with immune cells is warranted to 
optimize a model for NASH. 
The nuclear receptor, Hepatocyte Nuclear Factor 4-alpha (HNF4α), regulated by 
the presence of FA is reported to modulate both xenobiotic and FA metabolism (Merrell 
and Cherrington, 2011).  It is to be noted that, CYP2A6, 2B6, 2C8, 2C9, 2C19, 2D6 and 
3A4/5 are controlled by upstream regulator HNF4α via PXR and CAR. Their xeno-sensing 
mechanism also plays a central role in lipid homeostasis and hepatocyte differentiation 
(Jover, Moya and Gómez-Lechón, 2009).  HNF4a deficient mice are shown to have 
increased lipid accumulation in the liver and reduced serum cholesterol and TG levels 




HNF4a which may contribute to the progression to steatosis as well as dysregulation in 
DMET. However, most of the nuclear receptors and transcriptional regulator could not be 
identified in the proteomics assay due to the low abundance in cells. 
Comparative analysis of transcriptomics and proteomics reveal important pattern 
of many proteins as seen in AKR1B10. However, there is a mismatch in DME mRNA and 
protein expression, this could be partly explained due to changes in posttranslational 
modifications and cellular location of proteins (Schwanhäusser et al., 2011). Recently, Liu 
et al. reviewed the relationship between mRNA and proteins under different scenarios 
(Liu, Beyer and Aebersold, 2016). They concluded that the correlations may depend on 
many factors including applied techniques used in quantification of mRNA and protein, 
cell state, and posttranscriptional and posttranslational processes. These might have 
caused the observed variability. This may cause the change in expression pattern of the 
endpoints, primarily due to the time of harvest from the vitro culture. Also, the samples for 
the protein expression study in HepaRG cells were harvested from P17-P20 in comparison 
to P16 for mRNA samples. We believe the different passages are causing variability and 
leading to loss of significance in the assessment of CYP450 proteins that are generally 
present in low abundance in HepaRG cells. 
In conclusion, our study presents an in-vitro model of steatosis demonstrating that 
lipid-loaded HepaRG cells are a suitable model for studying the effect of NAFLD on drug-
metabolizing enzymes and transporters.  Utilizing transcriptomics and proteomics data, 
we established the experimental model (2:1 O/P in HepaRG) showed a molecular 
signature that closely resembled hepatic steatosis leading to steatohepatitis.  Additionally, 
we reported a significant downregulation of various DMET genes, along with a proposed 




can be a valuable in-vitro tool to model the disposition of new chemical entities in the 









Figure 3.1. Model development of cellular steatosis by Oil Red O staining and cell 
viability assay.   
(Fig 3.1-I) HepaRG cells were treated for 24h, 48h, 72h with control (A, C, E) vs. 0.5 µM 
of O/P 1:2 treatment (B, D, F).  Images were taken under a light microscope at 20X 
magnification.  The scale bars denote 85 µm.  (Fig 1-II) For quantitative analysis of fat 
incorporation, Oil Red O stain was extracted and measured, OD @ 492 nm, following O/P 
treatment for 24, 48 and 72h respectively. Mean + SD (assayed in triplicate) are 
represented as relative to control cells.  (Fig 1-III) Cells were incubated in the presence of 
increasing concentrations from 0.1 - 2.0 mM of O/P (1:2) mixture for 72h.  Data from the 
WST-1 tests are depicted as means + SD (three biological replicates) and given relative 
to control cells (NC). PC (positive control) cells were treated with 0.1 mM of clotrimazole.  
A non-toxic and steatosis-inducing concentration of 0.5 mM O/P at 72h incubation was 
















   
Figure 3.2: Model development of cellular steatosis by Oil Red O staining and cell 
viability assay.   
(Fig 1-I) HepaRG cells were treated for 24h, 48h, 72h with control (A, C, E) vs. 0.5 µM of 
O/P 1:2 treatment (B, D, F).  Images were taken under a light microscope at 20X 
magnification.  The scale bars denote 85 µm.  (Fig 1-II) For quantitative analysis of fat 
incorporation, Oil Red O stain was extracted and measured, OD @ 492 nm, following O/P 
treatment for 24, 48 and 72h respectively. Mean + SD (assayed in triplicate) are 
represented as relative to control cells.  (Fig 1-III) Cells were incubated in the presence of 
increasing concentrations from 0.1 - 2.0 mM of O/P (1:2) mixture for 72h.  Data from the 
WST-1 tests are depicted as means + SD (three biological replicates) and given relative 
to control cells (NC). PC (positive control) cells were treated with 0.1 mM of clotrimazole.  
A non-toxic and steatosis-inducing concentration of 0.5 mM O/P at 72h incubation was 



























Figure 3.3: Model validation of cellular steatosis.   
Differentiated HepaRG cells were treated with BSA alone (control) or with 0.5 µM 
palmitate: oleate (1: 2) (FA treatment) for 72 h prior to assaying triglyceride (A) and 
cholesterol (B) content.  (C) The mean level of reactive oxygen species (ROS) detected 
via measuring malondialdehyde (MDA) as an indicator of oxidative stress is shown.  (D) 
Cells were treated for 12h in serum free media (Starvation).  Cells were then stimulated 
with insulin (1, 10, 100 nM) for 10 min before harvest.  Phosphorylated Akt (Ser473) and 
total Akt were assayed in ELISA kit.  Error bars represent standard deviation.  All samples 
were assayed in triplicates.  Asterisks indicate a significant (*P < 0.05; **P <0.01; ***P 










Figure 3.4: Differential expressed genes and proteins in HepaRG cells with FA treatment.   
(A)  Venn diagram indicating the differentially up- and down-regulated genes quantified using proteomics and transcriptomics studies; 
based on log FC > 0.58; pvalue < 0.05. (B) Venn diagram showing the differentially up- and down-regulated proteomics quantified 
using SWATH-MS. (C) Listed are the significant gene expression change that predict the model disease state to closely resemble 
steatosis, microvesicular hepatic steatosis, steatohepatitis as well as non-alcoholic fatty liver upon fatty acids addition to HepaRG cells. 


















Figure 3.5: Changes in protein expression involved in glycolysis and in the 
progression of NAFL.  
(A) The protein expression quantified by SWATH-MS of glycolytic proteins in control and 
FA treated HepaRG cells are shown. (B, C) The proteins involved in hepatocellular injury 
as well as markers for the progression of NAFL are shown. The expression of proteins is 
expressed as pmol/mg of protein. The figure is the mean of protein expression among the 




































































                                  
 
 
Figure 3.6: Transcripts and proteins involved in lipid catabolism, lipid synthesis and 
lipid transport. 
The figure denotes the log fold change (FC) of expression in FA treatment vs. control. The 
mRNA and protein response are denoted as shown. The figure is shown as mean of log 


















































































Figure 3.7: Fold change (logFC) of drug metabolizing genes and proteins upon 
treatment.  
Differentiated HepaRG cells were treated with BSA alone (control) or 0.5 µM 
palmitate:oleate (1: 2) (FA treatment) for 72 h prior to SWATH-MS based proteomics 
analysis.  (A) Heat map illustrating cytochrome P450 (CYP), Other Phase 1, Phase 2 and 
transporters mRNA and proteins are shown. Log FC of mRNA and protein expression as 
shown in the figure (B) Heat map of nuclear receptors and transcriptional regulators are 
expressed as log FC of mRNA and proteins. (C) mRNA expression of control and fatty 
acid treated HepaRG cells from q-PCR are expressed.  All samples were assayed in 
triplicates and samples are represented as an average of log2FC.  X denotes absence of 






















































































   
































































































Figure 3.8: CYP3A4 functional activity in control and fatty acid treatment.   
CYP3A4 enzyme activity assessed at different substrate concentration (30, 10, 3, 1, 0.5 
µM) show significant downregulation upon FA treatment. The significance was calculated 




















































Table 3.1: Comparison of transcriptional expression profile of lipid loaded HepaRG model and biobank liver samples 
Gene Name Description RNA-seq/ FC P value 
q-PCR/ FC 
(Steatosis/cntrl) P value 
(From current study) (Starmann et al., 2012)  
SUSD2 sushi domain containing 2 6.53E-01 2.50E-16 1.47E+00 6.90E-02 
ACSL4 
acyl-CoA synthetase long-chain family 
member 4 1.51E+00 4.66E-11 2.11E+00 2.90E-02 
ATF3 crystallin lambda 1 6.75E-01 2.18E-09 1.57E+00 1.74E-01 
INMT indolethylamine N-methyltransferase 3.24E-01 3.75E-09 1.03E+00 9.19E-01 
MAT1A methionine adenosyltransferase 1A 6.96E-01 6.23E-09 8.55E-01 3.21E-01 
LUM lumican 1.33E+00 1.83E-07 1.45E+00 6.10E-02 
ACSL5 
acyl-CoA synthetase long-chain family 
member 5 1.25E+00 4.28E-06 1.38E+00 4.90E-02 
PNPLA3 
patatin like phospholipase domain 
containing 3 7.62E-01 4.20E-05 2.15E+00 2.00E-03 
SH3KBP1 
SH3 domain containing kinase binding 
protein 1 1.31E+00 2.18E-04 1.38E+00 1.43E-01 
ID3 inhibitor of DNA binding 3, HLH protein 7.10E-01 2.66E-04 1.01E+00 9.68E-01 
SQSTM1 sequestosome 1 1.17E+00 2.30E-03 1.32E+00 1.30E-01 
AKR1B10 
aldo-keto reductase family 1 member 





DGAT2 diacylglycerol O-acyltransferase 2 8.72E-01 1.49E-02 1.31E+00 2.31E-01 
CYP3A43 
cytochrome P450 family 3 subfamily A 
member 43 3.26E-01 3.41E-02 7.77E-01 4.05E-01 
ITGA3 integrin subunit alpha 3 1.09E+00 1.01E-01 1.45E+00 1.33E-01 
STMN1 stathmin 1 1.07E+00 2.22E-01 NA NA 
GSTM1 glutathione S-transferase mu 1 8.53E-01 2.27E-01 NA NA 
KRT18 keratin 18 1.05E+00 3.46E-01 1.18E+00 3.06E-01 
CAT catalase 9.58E-01 3.64E-01 7.22E-01 5.21E-01 
NR0B2 
nuclear receptor subfamily 0 group B 
member 2 6.44E-01 3.78E-01 2.27E+00 1.00E-03 
DEFB1 defensin beta 1 9.46E-01 5.26E-01 2.36E+00 1.00E-03 
LRRFIP2 LRR binding FLII interacting protein 2 1.01E+00 8.97E-01 1.80E+00 5.00E-03 
KRT8 keratin 8 1.01E+00 9.07E-01 1.65E+00 4.10E-02 









value) Ratio Molecules 
FXR/RXR Activation 24.2 0.278 
APOA4, TF, SLC10A1, SLC22A7, G6PC, RBP4, NR5A2, APOC1, APOC3, 
APOM, KNG1, BAAT, AMBP, APOL1, ALB, UGT2B4, LIPC, PKLR, ABCG5, FGA, 
ABCG8, CYP8B1, VTN, SAA2, MLXIPL, APOA2, FETUB, LCAT, APOE, 
SULT2A1, AHSG, HPR, CYP7A1, TTR, NR1I2 
LXR/RXR Activation 21.4 0.264 
IL1RL1, APOA4, TF, LBP, RBP4, IL6, APOC1, APOC3, APOM, KNG1, AMBP, 
APOL1, ALB, MYLIP, CCL7, TNFRSF1B, ABCG5, FGA, ABCG8, CD36, VTN, 





UGT2B4, CYP3A7, CYP4X1, UGT2B10, UGT1A7 (includes others), UGT2B7, 
CYP1A1, SULT1A2, CYP3A4, SULT1E1, UGT1A1, CYP2C9, CYP4B1, CYP2B6, 
CYP1A2, UGT2B15, UGT2A3, CYP2C8, CYP3A5, SULT2A1, CYP2A6 (includes 
others) 
LPS/IL-1 Mediated 
Inhibition of RXR 
Function 
15.7 0.158 
IL1RL1, CYP3A7, CYP4A11, SLC10A1, SULT1A2, GSTA2, CYP3A4, LBP, 
NR5A2, APOC1, CYP2C9, FMO5, ACSL1, CYP2B6, GSTA1, CYP2A6 (includes 
others), GSTT2/GSTT2B, ALDH1L1, FABP4, LIPC, TNFRSF1B, ABCG5, 
ALDH6A1, SULT1E1, ABCG8, CHST11, ACSL4, CYP2C8, ACSL3, CYP3A5, 
APOE, SULT2A1, CYP7A1, CHST15, NR1I2 
Nicotine Degradation 15.3 0.317 
UGT2B4, CYP3A7, CYP4X1, UGT2B10, UGT1A7 (includes others), UGT2B7, 
CYP1A1, CYP3A4, UGT1A1, CYP2C9, FMO5, CYP4B1, CYP2B6, CYP1A2, 
UGT2B15, UGT2A3, CYP2C8, CYP3A5, INMT, CYP2A6 (includes others) 
Estrogen 
Biosynthesis 13.1 0.385 
HSD17B3, HSD17B2, CYP3A7, CYP4X1, CYP1A1, CYP3A4, CYP2C9, AKR1C4, 
CYP4B1, CYP2B6, CYP1A2, CYP2C8, CYP3A5, HSD17B13, CYP2A6 (includes 
others) 
PXR/RXR Activation 12.7 0.277 
CYP3A7, UGT1A7 (includes others), G6PC, GSTA2, CYP3A4, IL6, UGT1A1, 
CYP2C9, IGFBP1, CYP2B6, CYP1A2, CYP2C8, CYP3A5, SULT2A1, GSTA1, 
CYP2A6 (includes others), CYP7A1, NR1I2 
Serotonin 
Degradation 12.6 0.253 
UGT2B4, DHRS9, ALDH1L1, ADH1C, UGT2B10, UGT1A7 (includes others), 
UGT2B7, SULT1A2, ADH1A, ADH4, SULT1E1, UGT1A1, ADHFE1, ADH1B, 






Degradation 10.5 0.44 
CYP4B1, CYP2B6, CYP1A2, CYP3A7, CYP4X1, CYP2C8, CYP1A1, CYP3A5, 
CYP3A4, CYP2C9, CYP2A6 (includes others) 
Acetone Degradation 10.1 0.407 CYP4B1, CYP2B6, CYP1A2, CYP3A7, CYP4X1, CYP2C8, CYP1A1, CYP3A5, CYP3A4, CYP2C9, CYP2A6 (includes others) 
Atherosclerosis 
Signaling 10 0.165 
APOA4, COL5A3, COL1A1, PLA2G6, RBP4, IL6, APOC1, APOC3, COL18A1, 
APOM, CXCL8, CD36, CCL2, APOA2, RARRES3, LCAT, PLA2G12B, APOE, 
ICAM1, APOL1, ALB 
Xenobiotic 
Metabolism Signaling 8.92 0.105 
UGT2B11, CYP3A7, UGT1A7 (includes others), CYP1A1, SULT1A2, GSTA2, 
CYP3A4, IL6, CYP2C9, FMO5, CYP2B6, GSTA1, FGFR3, UGT2B4, 
GSTT2/GSTT2B, ALDH1L1, UGT2B10, UGT2B7, ALDH6A1, MAP3K12, 
SULT1E1, UGT1A1, CHST11, CYP1A2, UGT2B15, CYP2C8, CYP3A5, 
SULT2A1, CHST15, NR1I2 
Coagulation System 8.65 0.314 F12, F7, KNG1, FGB, FGA, F10, SERPINC1, PLG, SERPIND1, FGG, F13B 
Acute Phase 
Response Signaling 8.4 0.129 
TF, TNFRSF1B, SOCS3, FGA, LBP, RBP4, IL6, CRP, PLG, FGG, SOD2, HRG, 
SAA2, FGB, APOA2, SOCS1, AHSG, AMBP, RBP5, SERPIND1, ALB, TTR 
Extrinsic Prothrombin 
Activation Pathway 8.33 0.5 F12, F7, FGB, FGA, F10, SERPINC1, FGG, F13B 
Thyroid Hormone 
Metabolism II (via 
Conjugation and/or 
Degradation) 
7.84 0.268 UGT2B4, UGT2B10, UGT1A7 (includes others), UGT2B7, UGT2B15, UGT2A3, SULT1A2, DIO1, SULT1E1, SULT2A1, UGT1A1 
Intrinsic Prothrombin 
Activation Pathway 7.72 0.262 





7.64 0.538 AKR1D1, BAAT, CYP3A4, SCP2, AKR1C4, CYP8B1, CYP7A1 
Ethanol Degradation II 7.21 0.27 DHRS9, ACSL1, ALDH1L1, ADH1C, ADH1B, ADH1A, PECR, ADH4, ADH6, ADHFE1 
Hepatic Fibrosis / 
Hepatic Stellate Cell 
Activation 
6.47 0.109 
IL1RL1, COL7A1, BAMBI, KDR, TNFRSF1B, COL6A1, COL27A1, CTGF, 






Table 3.3: Classification of differentially expressed genes upon FA treatment vs. control predictive of physiological disease 
state 








ACSL1 acyl-CoA synthetase 
long chain family 
member 1 
0.775 2.73E-08 Cytoplasm enzyme 
ENSG00000068366 ACSL4 acyl-CoA synthetase 
long chain family 
member 4 
0.602 6.25E-05 Cytoplasm enzyme 
ENSG00000130203 APOE apolipoprotein E -0.723 9.44E-06 Extracellul
ar Space 
transporter 









ENSG00000187048 CYP4A11 cytochrome P450 
family 4 subfamily A 
member 11 
-1.28 2.48E-06 Cytoplasm enzyme 
ENSG00000185000 DGAT1 diacylglycerol O-
acyltransferase 1 
-0.711 4.67E-05 Cytoplasm enzyme 
ENSG00000170323 FABP4 fatty acid binding 
protein 4 







-1.22 4.68E-07 Cytoplasm phosphatase 
ENSG00000171766 GATM glycine 
amidinotransferase 
-0.962 4.84E-08 Cytoplasm enzyme 
ENSG00000124713 GNMT glycine N-
methyltransferase 









ENSG00000146678 IGFBP1 insulin like growth 
factor binding protein 1 
 1.04 2.47E-05 Extracellul
ar Space 
other 
ENSG00000136244 IL6 interleukin 6  1.28 0.00293 Extracellular 
Space 
cytokine 
ENSG00000127528 KLF2 Kruppel like factor 2 -0.98 0.0315 Nucleus transcription 
regulator 
ENSG00000129988  LBP lipopolysaccharide 
binding protein 
0.815 4.84E-08 Plasma 
Membrane 
transporter 
ENSG00000166035  LIPC lipase C, hepatic type -0.817 0.0059 Extracellul
ar Space 
enzyme 












-1.01 0.0303 Cytoplasm enzyme 
ENSG00000140398 NEIL1 Nei like DNA 
glycosylase 1 





PLIN2 perilipin 2 1.39 4.21E-10 Plasma 
Membrane 
other 
ENSG00000130988 RGN regucalcin -1.01 3.12E-04 Nucleus enzyme 
ENSG00000181856 
SLC2A4 solute carrier family 2 member 4 -0.731 0.0184 
Plasma 
Membrane transporter 
ENSG00000112096 SOD2 superoxide dismutase 2 0.896 7.55E-09 Cytoplasm enzyme 











ENSG00000213996 TM6SF2 transmembrane 6 
superfamily members 
2 
-1.41 0.00787 Plasma 
Membrane 
other 
ENSG00000265972 TXNIP thioredoxin interacting 
protein 





Table 3.4: Classification of differentially expressed drug metabolizing genes and proteins upon FA treatment vs. control 




ENSG00000187758 alcohol dehydrogenase 1A (class I); 
alpha polypeptide  
ADH1A -1.30 1.01E-06 
ENSG00000196616 alcohol dehydrogenase 1B (class I); 
beta polypeptide  
ADH1B -1.45 5.93E-09 
ENSG00000248144 alcohol dehydrogenase 1C (class I); 
gamma polypeptide  
ADH1C -1.96 1.41E-08 
ENSG00000198099 alcohol dehydrogenase 4 (class II); pi 
polypeptide 
ADH4 -1.70 6.97E-09 
ENSG00000140505 cytochrome P450 family 1 subfamily A 
member 2  
CYP1A2 -3.25 1.25E-06 
ENSG00000255974 cytochrome P450 family 2 subfamily A 
member 6  
CYP2A6 -2.61 2.49E-06 
ENSG00000197408 cytochrome P450 family 2 subfamily B 
member 6  
CYP2B6 -2.02 1.60E-04 
ENSG00000138115 cytochrome P450 family 2 subfamily 
C member 8  
CYP2C8 -1.48 1.62E-08 
ENSG00000138109 cytochrome P450 family 2 subfamily 
C member 9  
CYP2C9 -2.00 2.17E-10 
ENSG00000160868 cytochrome P450 family 3 subfamily A 
member 4  
CYP3A4 -1.87 1.60E-04 
ENSG00000106258 cytochrome P450 family 3 subfamily A 
member 5  
CYP3A5 -0.80 4.29E-06 
ENSG00000160870 cytochrome P450 family 3 subfamily A 
member 7  
CYP3A7 -1.29 2.98E-03 
ENSG00000187048 cytochrome P450 family 4 subfamily A 
member 11  
CYP4A11 -1.28 2.48E-06 
ENSG00000186115 cytochrome P450 family 4 subfamily F 
member 2  




ENSG00000167910 cytochrome P450 family 7 subfamily A 
member 1  
CYP7A1 -2.71 7.50E-06 
ENSG00000180432 cytochrome P450 family 8 subfamily B 
member 1  
CYP8B1 -1.61 6.80E-06 
ENSG00000131781 flavin containing monooxygenase 5  FMO5 -1.21 9.44E-06 
 ENSG00000122787 aldo-keto reductase family 1-member 
B10  
 
AKR1B10 2.17 1.41E-06 
ENSG00000198610 aldo-keto reductase family 1-member C4  
 









ENSG00000241119 UDP glucuronosyltransferase family 
1-member A9  
UGT1A9 -1.40 7.55E-07 
ENSG00000196620 UDP glucuronosyltransferase family 
2-member B15  
UGT2B15 -0.95 9.82E-08 
ENSG00000135220 UDP glucuronosyltransferase family 
2-member A3  
UGT2A3 -0.68 4.72E-06 
ENSG00000171234 UDP glucuronosyltransferase family 
2-member B7  
UGT2B7 -1.09 8.72E-08 
ENSG00000213759 UDP glucuronosyltransferase family 
2-member B11  
UGT2B11 -1.27 1.39E-04 
ENSG00000133433 glutathione S-transferase theta 2B  GSTT2B -1.07 8.48E-03 
ENSG00000243955 glutathione S-transferase alpha 1  
 
GSTA1 -0.91 6.51E-08 
ENSG00000105398 
 














ENSG00000121270 ATP binding cassette subfamily C 
member 11  
ABCC11 -1.36 3.13E-05 
ENSG00000143921 ATP binding cassette subfamily G 
member 8  
ABCG8 -0.97 6.30E-04 
ENSG00000138075 ATP binding cassette subfamily G 
member 5  




ENSG00000117834 solute carrier family 5 member 9  SLC5A9 -1.23 1.22E-05 
ENSG00000100652 
 
solute carrier family 10 member 1  SLC10A1 -1.63 5.91E-10 
ENSG00000137491 solute carrier organic anion 
transporter family member 2B1  
SLCO2B1 -1.49 1.02E-06 
ENSG00000134538 solute carrier organic anion 
transporter family member 1B1  







ENSG00000126368 nuclear receptor subfamily 1 group D 
member 1  
NR1D1 -0.52 2.11E-03 
ENSG00000144852 nuclear receptor subfamily 1 group I 
member 2  
NR1I2 -1.18 3.70E-06 
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ANXA1 - Annexin A1 
APOA4 - Apolipoprotein A-IV 
APOE - Apolipoprotein E 
APPL1 - DCC-interacting protein 13-alpha 
ATP1A2 - Sodium/potassium-transporting ATPase subunit alpha-2 
BCAT2 - Branched-chain-amino-acid aminotransferase 
CALD1 - Caldesmon 
CLTB - Clathrin light chain B 
DBNL - Drebrin-like protein 
EIF4H - Eukaryotic translation initiation factor 4H 
EIF5B - Eukaryotic translation initiation factor 5B 
G6PC - Glucose-6-phosphatase 
GMPPA - Mannose-1-phosphate guanyltransferase alpha 
GSTA4 - Glutathione S-transferase A4 
H2AFY2 - Core histone macro-H2A.2 
HMGB1 - High mobility group protein B1 
KRT10 - Keratin, type I cytoskeletal 10 
LTF - Lactotransferrin 
NAFLD - Nonalcoholic fatty liver disease 
NASH - Nonalcoholic steatohepatitis 
NBPF7 - Putative neuroblastoma breakpoint family member 7 
NSUN2 - RNA cytosine C(5)-methyltransferase NSUN2 
NT5C - 5'(3')-deoxyribonucleotidase, cytosolic type 
PALLD - Palladin 
PDCD5 - Programmed cell death protein 5 
PIGR - Polymeric immunoglobulin receptor 
PLIN2 - Perilipin-2 





PRKACB - cAMP-dependent protein kinase catalytic subunit beta 
PTMS - Parathymosin 
RAB23 - Ras-related protein Rab-23 
RBM4 - RNA-binding protein 4 
RBM5 - RNA-binding protein 5 
SH3BGRL3 - SH3 domain-binding glutamic acid-rich-like protein 3 
SLC26A2 - Sulfate transporter 
SLC35A3 - UDP-N-acetylglucosamine transporter 
SNX1 - Sorting nexin-1 
SNX6 - Sorting nexin-1 
TSN - Translin 






Background & Aims: Non-alcoholic fatty liver disease (NAFLD) is a global epidemic, 
manifested in over 10% of the world population, although often is undiagnosed. Liver 
biopsies are the only gold standard available for the confirmation of the disease state. 
Other non-invasive diagnostics such as ultrasound and MRI are inaccurate or expensive 
for routine use. Many markers for disease state are available that detect the onset of 
inflammation and fibrosis from moderate-to-high accuracy. However, there is a major 
shortcoming in specific biomarkers that can distinguish NAFLD livers from normal in early 
stages of the onset of disease. 
Methods: SWATH-MS based Data-independent acquisition (DIA) strategy is used in the 
proteomics analysis due to its ability in quantification of low-abundant proteins with high 
accuracy. Hence a DIA based strategy is used to evaluate the dysregulated proteins in 
two in vitro models of hepatic steatosis and to compare it with human liver tissue (n=116) 
showing progressive stages of NAFLD. 
Results: More than 2,500 proteins were identified in HepaRG and human hepatocyte 
model as well as human liver tissue.  Within the hepatocyte model, 40 proteins were 
dysregulated in steatosis. These proteins were screened in liver tissue and 6 common 
proteins (PLIN2, ANAX1, H2AFY2, APOE, GCFHR, SNX1) showed significant changes in 
protein expression. In addition, receiver operative curve (ROC) analysis revealed all 
markers were relevant in the prediction of the disease state with moderate-to-high 
selectivity and specificity. Especially, PLIN2, ANAX1 and H2AFY2 showed receiver 
operative area under the curve (ROAUC) ≥ 0.7. 
Keywords 







Nonalcoholic fatty liver disease (NAFLD) is reported to be the leading cause 
of end stage liver disease and liver transplantation 1. It affects up to 30% of the 
adult population, especially in western countries 2. Moreover, 10-15% of the 
patients diagnosed with NASH, develop cirrhosis and hepatocellular carcinoma 3. 
Despite the recent advancement in diagnostics, liver biopsy is the only gold 
standard method for confirmation of NAFLD 4.   
Histological testing of liver biopsies, along with multiple scoring scales and 
algorithms, are employed to classify the progression of the disease 5. However, 
liver biopsies are invasive, expensive and poorly accepted among the patient 
population. In addition, owning to the heterogenicity of lipid localization in liver as 
seen with severity of steatosis, diagnosis from liver biopsies may be biased and 
lead to misclassification 6. Noninvasive imaging techniques have improved over 
time and are used to help determine the progression of steatosis, inflammation, 
hepatocellular ballooning, fibrosis, as well as liver stiffness 4, 7. However, 
ultrasound fail to detect steatosis with the grade of < 20%, in addition, more precise 
diagnostics such as MRI, are expensive for routine testing 4. Hence, biomarkers 
that best predict the severity and progression of disease state are therefore 
needed for diagnosis and therapy. In addition, it can also greatly improve the 
current drug development process for NAFLD. Due to the complexity involved in 
the disease progression of NAFLD, it is highly unlikely that a single biomarker can 
precisely delineate steatosis and NASH group. Henceforth, a list of proteins that 





gender and diabetes) would present the robustness for probable biomarker 
identification. 
With the advent of novel proteomics technologies, multiple studies have 
reported to identify various biomarkers in NAFLD. Bell et al. reported 55 as well as 
15 proteins that were dysregulated in NAFLD and NASH with advanced fibrosis 
along with NASH and NASH with advanced fibrosis, respectively 8, 9. However, not 
much is known about the dysregulated proteins between simple steatosis and 
NASH groups. Proteomics employing sequential acquisition of theoretical mass 
spectra (SWATH-MS) is a powerful tool that aims to determine the relative amount 
of proteins from low-throughput biological samples 10-12. Data independent 
acquisition based total protein approach (DIA-TPA) is more commonly used in 
untargeted proteomics, to compare the protein levels between the groups. This 
approach is sensitive to capture the low abundant proteins extracted from cells as 
well tissue homogenates, and hence an ideal tool for biomarker discovery 12.  
The objective of this study is to identify a list of secretory hepatic proteins 
associated with the progression of disease. To achieve this, we compared the 
relative protein expression in human hepatocyte and HepaRG-based models for 
hepatic steatosis with human liver tissue showing progressive stages of NAFLD. 
This comprehensive comparison provides a panel of proteins that may act as 





2. Material and Methods 
2.1 Chemicals and Reagents.  
TPCK-treated trypsin, trypsin digested β-galactosidase and mass spectrometer 
tuning solution were purchased from SCIEX, Framingham, MA. Acquity UPLC Peptide 
BEH C18 analytical column and VanGuard pre-columns were procured from Waters Corp. 
(Waltham, MA). IN). Bovine serum albumin, sodium deoxycholate and iodoacetamide 
(IAA) were procured from Sigma Aldrich (St. Louis, MO). MS grade acetonitrile and formic 
acid were purchased from ThermoFisher, Waltham, MA. 
2.2  Cell Culture 
The HepaRG and cHH were cultured as per manufacturer’s protocol.  
Cryopreserved pooled human hepatocytes (cHH). Pooled donors of cHH, were 
obtained from Xenotech, LLC (Kansas City, KS). Demographic information of the 5 pooled 
cHH is listed in Table 4.1. cHH were thawed in a 37 °C water bath for ~80 seconds. Vials 
were inverted transferred to pre-warmed OptiThaw media (K8000). Upon centrifugation at 
100 x g for 5 minutes at room temperature or 2-8°C, cells were washed. After thawing, the 
cell pellets were resuspended in OptiPlating media. The cells were diluted to 1 million 
cells/mL and seeded onto the collagen coated 6-well plate. Following this, the cells were 
allowed to attach for 4 h and the media was changed to OptiIncubate Hepatocyte Media 
(K8400) and allowed to incubate for 24 h. Upon 24 h, media containing 0.5 mM of fatty 
acids (oleate and palmitate 1:2) conjugated to BSA were added to treatment group in 
comparison to control. After 72 h of treatment, the cells were washed and scraped 
(CELLTREAT Scientific Products, Catalog No. #229310, Pepperell, MA) in ice-cold DPBS 
(ThermoFisher Scientific, Catalog No. #14040117, Waltham, MA) and 5-6 million cells 





HepaRG cells. Frozen undifferentiated HepaRG cells were purchased from Biopredic 
International (Rennes, France). The cells were grown for 2 weeks in William’s E media 
(ThermoFisher Scientific, Catalog No. #12551032, Waltham, MA), containing 1% 
glutamine (ThermoFisher Scientific, Catalog No. # A1286001, Waltham, MA), 1% 
penicillin/streptomycin and 10% HepaRG growth supplement (Lonza Inc., Catalog No. 
#ADD711C, Walkersville, MD) in 6-well plate. Following growth phase, cells were 
differentiated in-house for 2 weeks in William’s E media, 1% glutamine, 1% 
penicillin/streptomycin and 10% HepaRG differentiation supplement (Lonza Inc., Catalog 
No. #ADD721C, Walkersville, MD) and maintained at 37°C with 21% O2 and 5% CO2 
throughout the culture with media changed every 3 days. Upon differentiation, HepaRG 
cells were cultured in basal media containing William’s E media, 100 U/mL penicillin, 100 
µg/mL streptomycin, 2 mM glutamine, 5 µg/mL insulin (Sigma-Aldrich, Catalog No. #I-034, 
St. Louis, MO) and 50 µM hydrocortisone hemisuccinate (Sigma-Aldrich, Catalog No. 
#H2270, St. Louis, MO). Upon differentiation, the cells were treated with fatty acid media 
as described above. Approximately 8-10 million cells were harvested by cell scraping for 
proteomic analysis.  
2.3  Oil Red O Staining 
Pooled cHH treated with 0.5 mM FA or control for 72h was analyzed for neutral lipid 
accumulation.  Cells were washed twice with 1X PBS and fixed with 4% paraformaldehyde 
(Sigma-Aldrich, Catalog# 100496, Saint Louis, MO) for 30 min in room temperature (RT).  
Following this, 500 µl of working Oil Red O (ORO) solution (3 parts of stock ORO and 2 
parts of dH2O) (Sigma-Aldrich, Catalog# O0625, Saint Louis, MO) was added and 
incubated at RT for 20 min.  The cells were washed 3X with distilled water (dH2O), and 
500 µL of hematoxylin (Sigma-Aldrich, Catalog# H3136, Saint Louis, MO) was added for 





(Life Technologies, Model# M7000, Foster City, CA).  The extent of neutral lipid 
accumulation was quantified after extraction in 100% isopropanol, and the absorbance 
was measured at 492 nm using a SpectraMax plate reader (Molecular Devices, Model# 
M2, Sunnyvale, CA). 
2.4  Proteomics sample preparation  
Cell pellets were homogenized in 500 µl of homogenization buffer (8 M urea, 50 
mM Triethylammonium bicarbonate, 10 mM DTT v/v) using a bead homogenizer (Omni 
Bead Ruptor, Kennesaw GA). 50 mg of human liver tissue (HLT) (n=116) was 
homogenized in 1000 µl of homogenization buffer, in similar fashion. Samples were then 
spun at 1,000 g for 5 min and the supernatant was collected. The total protein 
concentration was determined using Pierce BCA protein assay (ThermoFisher Scientific, 
Catalog No. #23227, Waltham, MA).  
2.5  In-solution trypsin digestion  
Protein digestion was conducted as previously described with few adaptations. 
Samples (250 µg protein) were spiked with 2 µg of BSA and denatured with 25 µL of DTT 
(100 mM) at 35°C for 30 min in a shaking water bath (100 rpm) (Precision Scientific, 
Catalog No. #66800, Chicago, IL). After denaturation, samples were alkylated in the dark 
with 25 µL of IAA (200 mM) for 30 min at room temperature. Samples were then 
concentrated using the cold water, methanol and chloroform (1:2:1) precipitation method 
(centrifugation at 10000 rpm, 5 min at 10°C) (Eppendorf, Catalog No. #5810 R, Hamburg, 
Germany). The protein pellet was washed with ice-cold methanol and suspended in 100 
µL of 50 mM ammonium bicarbonate (pH ~8) containing 3% w/v sodium deoxycholate 
(DOC). Further, TPCK-treated trypsin (10 µg) was added to samples at a ratio of 1:25 





Pressure Biosciences Inc., Easton, MA). The barocycler was run at 35°C, for 75 cycles 
with 60-sec pressure-cycle (50-sec high pressure, 10-sec ambient pressure, 25 kpsi). 
Subsequently, 10 µg trypsin was added again for futher digestion as mentioned above. 
Furthermore, to 110 µL of digested peptides sample, 10 µL of acetonitrile (1:1, v/v 
containing 5% formic acid) was added to precipitate DOC. Samples were spun (10,000 
rpm for 5 min at 10°C) to remove the precipitate and 100 µL supernatant was collected. 
Subsequently, 25 µL of the digested peptide sample was injected on the analytical column 
and were analyzed using LC-MS/MS method described below.  
2.6  LC-MS/MS method and SWATH-MS data analysis  
The LC-MS/MS method was used as previously developed without modifications. 
Homogenate samples were analyzed using SWATH-MS based spectra which were 
acquired for mass range m/z 400−1100 Da within SWATH window width of 10 m/z 
resulting in 70 overlapping mass windows per cycle, as described in the previous 
literature21. The DIA data was searched against Swiss-Prot identifiers (October 2016) 
and analyzed using Spectronaut™ Pulsar software (version 11.0, Biognosys AG, 
Schlieren, Switzerland) was used to obtain MS2 signal intensities of fragment ions from 
DIA data using default settings. Raw data files and search results are available at Japan 
Proteome Standard Repository (jPOSTrepo JPST000373, ProteomeXchange 
PXD008594). The SWATH-MS DIA data was matched with the reference spectral library 
generated from the DDA of pooled human liver samples using Protein Pilot. The DIA data 






The absolute protein abundance of each group was represented as pmol/mg of protein. 
2.7 Statistical and bioinformatic analysis  
Missing data with proteins more than 50% among the samples were omitted from analysis. 
For cell analysis, the proteins present in all replicates were only considered for analysis. 
Student's t-test with p value < 0.05 and log2FC cutoff of +/- 0.58 was used to identify 
differentially expressed proteins in pooled human hepatocytes, and the HepaRG cell lines. 
The data obtained from the cells were represented as means from quadruples. Proteins 
from human livers were analyzed using SPSS software v24.0. Protein data from human 
samples were ln (natural-log) transformed and analyzed using one-way ANOVA and post-
hoc analysis for multiple group comparison was conducted using Bonferroni test. In 
addition, the specificity and selectivity of proteins were analyzed using ROC cures on 
SPSS. P< 0.05 was considered significant. Prism 8 (GraphPad Inc., La Jolla, CA) was 




3.1 Overall workflow in the identification for dysregulated protein in disease state.  
The workflow followed in this manuscript is as illustrated in Fig. 4. 1. The samples obtained 
from cell model for hepatic steatosis was analyzed along with human liver tissue with 
progressive forms of NAFLD such as: normal (n=42) and  NAFL (n=34) based on Kleiner 
scoring 5. The data obtained from spectronaut was filtered for missing data and low 
abundance proteins which showed highly variable expression pattern. For the cell data, 
the proteins selected for analysis were present in all replicates (n=4). Similarly, for human 
tissue (n =116) the set criteria were missing data > 50% among all groupings and CV% < 





way 2781, 2653, 2580 unique proteins were identified in HLT, cHH and HepaRG cell lines, 
respectively (Fig. 4. 1). Among the 2653 protein 40 proteins were dysregulated in hepatic 
steatosis. This was compared with HepaRG steatosis model that showed a similar pattern 
for 7 proteins as described in Fig. 4. 4. All of these 40 proteins were matched with human 
liver tissue and using ANOVA and post hoc analysis for multiple comparison Bonferroni 
test (p <0.05), 6 proteins that showed significant difference were identified (Table 4. 3). 
3.2. Effect of fatty acid loading to human hepatocytes.  
Upon treatment, the pooled human hepatocytes showed increase in neutral lipid 
accumulation visualized at 72h utilizing ORO stain (Fig 4.2A and 4.2B).  In addition, we 
noticed a 6-fold increase in absorbance (492 nm) when treated with fatty acids in 
comparison to the control (p < 0.01) (Fig. 4. 2C). 
 
3.3 SWATH-MS based evaluation of proteins in human hepatocytes, HepaRG and 
human liver tissue.  
Upon filtering with set criteria, 2781, 2653, 2580 unique proteins were identified in HLT, 
cHH and HepaRG cell lines, respectively (Fig. 4.1). Among the groupings, 1967 proteins 
were common among the three groups (Fig. 4.2D). However, 130 proteins were present 
in HepaRG and HLT independently showing the abundance of biliary-epithelial-like cells 
in HepaRG other than the hepatocyte-like cells. In addition, 128 proteins in HLT was not 
shared in any other groupings due to the presence of cell types than hepatocytes alone. 
 
3.4 Dysregulated protein expression in hepatic steatosis as seen in human hepatocytes.  
In this model for hepatic steatosis, 41 proteins were dysregulated using the cutoff for 
log2FC +/- 0.58 and p-value < 0.05 (Fig.4.3C). Among the 40 proteins, 14 were 
downregulated (Fig. 4.3A) and 26 were upregulated (Fig.4.3B). Within the 14 





localized in the nucleus and 3 (EIF5B, NT5C, SLC35A3) in the cytoplasm. Secretory 
proteins, PIGR (-0.66), KRT10 (-0.61) and APOE (-0.61) as well as cytoskeleton proteins 
CALD1 (-0.95) and PALLD (-0.99) were identified to be significantly downregulated in 
steatosis. Moreover, among the 26 dysregulated proteins, 6 secretory proteins HMGB1 
(0.62), PDCD5 (0.63), APOA4 (0.78), TSTA3 (1.06), ANAX1 (1.31), LTF (2.33). Other 
proteins involved in lipid storage PLIN2 (2.45) as well as those involved in xenobiotic 
metabolism GSTA4 (1.13), cytoskeleton remodeling DBNL (0.62) were also upregulated. 
 
3.5 Dysregulated protein expression in hepatic steatosis as seen in combined model of 
HepaRG and human hepatocytes.  
Among the 40 proteins that were dysregulated in human hepatocytes, 7 proteins showed 
a common signature in HepaRG steatosis model as well. KRT10 and APOE were 
significantly downregulated. On contrast, TSN, ANXA1, PTMS and PLIN2 showed 
upregulation to the extent that is similar between hepatocyte and HepaRG model. 
 
3.6 Dysregulated proteins as possible markers of hepatic steatosis.  
The 40 proteins that were dysregulated in pooled human hepatocytes were used as a 
starting point to screen for the protein expression in liver tissue showing differential 
expression in NAFLD. Among the 40 proteins, 6 showed significant change in expression 
in disease state (Table 4.3). It was to be noted that, majority of the protein ANXA1, 
GCHFR, H2AFY2, PLIN2, SNX1 and APOE showed a significant change (p < 0.05) in the 
earlier stages of the disease with steatosis, hepatocellular ballooning with minimal/no 
lobular inflammation (Fig. 4.5). Moreover, PLIN2 showed an increase with progression of 
disease from NAFL to NASH (data not shown). Within this pool of 6 proteins, ANAX1 and 
APOE were secretory proteins and PLIN2 is associated with lipid droplets present in tissue 





 The specificity and selectivity of the markers were analyzed using ROC analysis. 
All 6 markers showed significance, however, PLIN2, H2AFY2 and ANAX1 showed 
ROAUC of ≥ 0.7 showing the potential to be good markers of disease state (Table 4.4). 
4 Discussion 
Non-alcoholic fatty liver disease (NAFLD) is the estimated, within next 20 years, 
the major cause of liver related morbidity and mortality 3. Liver biopsy is the only 
confirmatory test for the onset of the disease 1. Due to the invasiveness, substantial cost 
as well as variability associated in this testing method, novel non-invasive techniques for 
the diagnosis of NAFLD have been extensively studied for development, in the recent 
times. The absence of biomarkers at early stages of disease is responsible for late 
diagnosis, leading to undiagnosed NAFLD in general population. Therefore, identifying 
novel biomarkers to detect the onset of the disease as well as disease progression is the 
need of the hour.  
Proteomics is emerging as an efficient tool for its application in exploratory 
biomarker studies12. DIA based SWATH-MS approach is sensitive and highly reproducible 
method to measure low abundant proteins in complex biological matrices 10, 11, 15. Hence, 
SWATH-MS approach was used to screen our samples as illustrated in Fig. 1. The global 
proteome expression, in the invitro HepaRG and hepatocyte model for steatosis was 
compared with human liver tissue with varying degrees of NAFLD. In addition, the whole 
cell and tissue homogenate without fractionation was analyzed as it most closely 
resembled the physiological state.  
Upon analyzing the samples, the dysregulated proteins in human hepatocytes 
model for hepatic steatosis was performed using log2FC and pvalue < 0.05 (Figures 3A–
C). A few of the dysregulated proteins observed in human hepatocytes (PIGR, APOE, 





which validates the prominence of these markers in disease state 16. Furthermore, our 
analysis from liver samples from different stages of NAFLD demonstrate that PLIN2, 
ANXA1, GCHFR, SNX1, H2AFY2 and APOE were significantly altered in NAFLD in 
comparison to control groups. Moreover, PLIN2 and H2AFY2 showed log fold change 
(logFC) greater than 0.58 showing more pronounced deregulation. In addition, ROC 
analysis highlights the selectivity and sensitivity of the markers individually on the disease 
state prediction (Table 4). It shows that PLIN2, ANXA1 and H2AFY2 are good markers of 
disease state with ROAUC ≥ 0.7.  
It is important to note that most of the markers showed an altered expression 
pattern in the earlier stages of the disease (NAFL) rather than those observed in NASH 
(data not shown). This pattern could be because of the bias associated with the 
comparison of dysregulated proteins from the hepatocyte-steatosis model. Furthermore, 
the sample size is not large enough to conclude the markers definitively to predict NAFL. 
Hence, studies with larger sample sizes need to conducted to make more conclusive 
remarks. 
PLIN2 is an abundant hepatic protein associated with lipid droplets. Reports show 
staining pattern of perilipin to distinguish steatosis and non-alcoholic steatohepatitis in 
adults and pediatric population 17. In addition, PLIN2 is concentrated and detected in 
human urine and is used to differentiate renal carcinomas 18. However, it is a ubiquitous 
protein associated with adipocytes differentiation, protumorigenesis and steatosis in 
cardiomyocytes. Hence, its selectivity for a disease state prediction may lead to low 
confidence. Therefore, PLIN2 along with other markers needs to be assessed together for 
understanding NAFLD. ANXA1 is an anti-inflammatory protein secreted by the 
hepatocytes. Plasma levels of ANXA1 are shown to correlate with fatty liver index in type 





and hepatosteatosis. The evidences in literature alongside our observation in disease 
state suggest the probable role AnnexinA1 as a biomarker for NAFL. Nuclear protein 
H2AFY2, a variant of histone protein H2A is a repressor of gene expression and APOE is 
a lipoprotein secreted by the hepatocyte that is required for VLDL clearance from the 
blood. The role of GCHFR and SNX1 is yet to be explored in NAFLD.  
Many previous studies have explored the potential of multiple plasma proteins as 
biomarkers of NAFLD 9, 20. Most studies, focus on the hallmarks of the disease progression 
that is inflammation and fibrosis. Thereby, we notice the promising biomarkers in plasma 
known thus far, such as: adiponectin, CRP, resistin, leptin, RBP-4, IL-6 and TNFα in 
inflammation and fibrosis; CK-18 fragments in apoptosis; MCP-1 in hepatocellular 
ballooning; ALT levels in hepatocellular injury; as well as ferritin in fibrosis. However, there 
is not much know about the early stage predictors of the disease. Hence our work is novel 
in presenting the dysregulated proteins in earlier stages of NAFLD prior to the onset of 
NASH. 
 In summary, a DIA based proteomics using SWATH-MS was implemented to 
understand the relevant proteins in NAFLD progression. Furthermore, by utilizing in-vitro 
model for steatosis we were able to delineate the proteins associated particular to the 
changes in fatty-acid overload. With this approach we streamlined 6 proteins including 2 
secretory proteins (ANAX1 and APOE) along with PLIN2 that is all localized ubiquitously 



















Figure 4.1: Overview of the workflow followed in the biomarker identification.  
The HepaRG and pooled human hepatocytes model for hepatic steatosis were collected and 
analyzed using SWATH-MS. Simultaneously human liver tissue (n=116) homogenates were 
screened using SWATH-MS and the data was analyzed using spectronaut. Using set criteria, the 
number of proteins identified in the groups were 2580, 2653 and 2781 in HepaRG, human 
hepatocytes and human liver tissue, respectively. Finally, the dysregulated from human 
hepatocytes was matched with human liver tissue to identify 6 markers of disease state. 
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p-value < 0.05
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Figure 4.2: Hepatic steatosis in human hepatocytes.  
Accumulation of neutral lipids upon the addition of fatty acid mixture to the pooled human 
hepatocytes is shown in the panel A and B. (C) Shows the 6-fold increase in the 
absorbance of neutral lipids in the treatment when compared to the control. The results 
are represented as mean of quadruple with p < 0.01. (D) Shows the Venn diagram of the 
number of identified proteins in human liver tissue, hepatocytes and HepaRG, with 1967 














Figure 4.3: Dysregulated protein expression in FA treatment and control in human 
hepatocytes.  
(A) Heat map of downregulated proteins in human hepatocytes (B) Heat map of upregulated 
proteins in human hepatocytes (C) The volcano plot shows green spots that indicate the 
upregulated proteins in human hepatocytes (log2FC>0.58 and Pvalue<0.05). The red spots 



















































































































































































Figure 4.4: Comparison of protein changes in FA treatment and control in HepaRG 
model and human hepatocytes. 






Figure 4.5: Hepatic protein expression shows differential expression in human liver 
tissue grouped based on control and NAFL.  
The differential expression in control (n=42) and NAFL (n=34) in human liver tissue. * denotes P 




































































































Table 4.1 Demographic information of human liver samples 
 Control NAFL 
N 42 34 
















Body weight (kg) 83.5 (76.2 - 91.5) 89.8 (80.6 - 100.1) 





Table 4.2: Demographic information of pooled human hepatocytes. 
 Pooled human 
hepatocyte 
N 5 


























 Table 4.3: Data summary of the significantly altered proteins in NAFLD 
  Normal 95% CI NAFLD 95% CI  log2FC 








PLIN2 0.61 42 0.48 0.79 1.51** 35 1.08 2.11 1.29 
ANXA1 2.80 42 2.49 3.15 3.81** 35 3.26 4.44 0.44 
H2AFY2 0.24 42 0.20 0.27 0.41** 35 0.34 0.48 0.79 
SNX1 0.51 42 0.48 0.54 0.58* 35 0.54 0.63 0.20 
GCHFR 24.02 42 22.10 26.11 19.48* 35 17.50 21.69 -0.30 
APOE 2.48 42 2.21 2.78 3.07* 35 2.74 3.43 0.31 
 
ABBREVIATION: CI - Confidence Interval; FC - Fold Change; N = no. of subjects; PLIN2 - Perilipin 2; ANXA1 - Annexin A1; H2AFY2 - Core 
Histone; SNX1 - Sorting protein 1; GCHFR - GTP Cyclohydrolase I Feedback Regulator; APOE - Apolipoprotein E. The differential 



















PLIN2 0.770 0.056 0.000 
ANXA1 0.700 0.061 0.003 
H2AFY2 0.798 0.055 0.001 
SNX1 0.669 0.063 0.011 
GCHFR 0.688 0.061 0.005 
APOE 0.688 0.061 0.005 
 
 
ABBREVIATION: ROAUC - Reciever operative Area Under the Curve; PLIN2 - Perilipin 2; 
ANXA1 - Annexin A1; H2AFY2 - Core Histone; SNX1 - Sorting protein 1; GCHFR - GTP 
Cyclohydrolase I Feedback Regulator; APOE - Apolipoprotein E. The differential 
expression in human liver tissue. * denotes P value < 0.05 and ** denotes P-value < 0.01 using 





Table 4.5: Dysregulated proteins in hepatic steatosis using a human hepatocyte model. 
Localization Protein Symbol Protein Name Molecular process Log2(FC) 
Secretory protein ANXA1 Annexin A1 Immune response 1.31* 
APOA4 Apolipoprotein A-IV Cholestrol efflux, lipid homoestatis 
and lipid transport 
0.78 
APOE Apolipoprotein E APOE vital lipoprotein metabolism 0.62* 
HMGB1 High mobility group protein B1 Promotes inflamatory response 0.62 
KRT10 Keratin, type I cytoskeletal 10 KT10 dysregulation leads to 
impaired NF-kB activity via 
inhibition of Akt 
-0.59 




PDCD5 Programmed cell death protein 
5 
Apoptosis 0.63 
PIGR Polymeric immunoglobulin 
receptor 
Neutophil degranulation -0.66 
TSTA3 GDP-L-fucose synthase T cell mediated cytotoxicity 1.06 
          
Nuclear proteins APPL1 DCC-interacting protein 13-
alpha 
Activation of AKT1 pathway in 
insulin response 
1.21 
EIF4H Eukaryotic translation initiation 
factor 4H 





GCHFR GTP Cyclohydrolase I 
Feedback Regulator 
Phenylalanine metabolism and 
nitric oxide production 
0.65* 
NSUN2 RNA cytosine C(5)-
methyltransferase NSUN2 
Cell division 0.81 
PPP1R7 Protein phosphatase 1 
regulatory subunit 7 
Positive regulator of protein 
dephosphorylation 
-0.63 
PRKACB cAMP-dependent protein 
kinase catalytic subunit beta 
Cellular response to glycogen 
synthesis 
-0.82 
PTMS Parathymosin Immune response 0.76 
RBM5 RNA-binding protein 5 Apopotoptic pocess 0.95 
RBM4  RNA-binding protein 4 RNA binding protein -1.31 
SH3BGRL3 SH3 domain-binding glutamic 
acid-rich-like protein 3 
Cell redox homeostatis -0.65 
SNX1 Sorting nexin-1 Intracellular protein transport 0.64* 
SNX6 Sorting nexin-1 Intracellular protein transport -0.71 
TSN Tanslin Stimulates RNAi production for 
silencing the transcript from protein 
expression 
1.02 
H2AFY2 Core histone macro-H2A.2 Keratinocyte differentiation; 
regulation of gene expression 
0.92* 
          
Cytoplasmic 
protein 







Formation of glycolipids 0.82 
NBPF7  Putative neuroblastoma 
breakpoint family member 7 
unknown 1.01 
EIF5B Eukaryotic translation initiation 
factor 5B 
Translational initiation 0.62 
NT5C 5'(3')-deoxyribonucleotidase, 
cytosolic type 
Purine catabolism -0.77 
          
Cytoskeletal 
proteins 
CALD1 Caldesmon Increase the stiffness of actin 
filament and promote cellular 
contraction 
-0.95 
PALLD Palladin Increase the stiffness of actin 
filament and promote cellular 
contraction 
-0.99 
DBNL Drebrin-like protein Reorganization of actin 
cytoskeleton 
0.62 
          
Membrane protein ATP1A2 Sodium/potassium-transporting 
ATPase subunit alpha-2 
Sodium potasium transporter 
involved in wide range of 
processes 
0.92 





RAB23 Ras-related protein Rab-23 Intracellular protein transport 0.86 
SLC26A2 Sulfate transporter Sulfate transporters involved in 
bone formation 
0.95 
PLIN2 Perilipin-2 Lipid storage 2.45* 
          





Induce heterogenecity in LD in 
hepatocytes; BCAA are indicative 




Carbohydrate transport -0.98 
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This work demonstrates the utility of in vitro models of hepatocytes to aid in the 
identification of novel biomarkers in hepatic steatosis. In the first part of this work 
(Manuscripts II), we characterized different cell lines to choose the appropriate human 
carcinoma cell line for model development in NAFLD. Using this initial assessment, 
HepaRG cell line was chosen for model development with lipid loading using oleate and 
palmitate (1:2) at 0.5 mM for 72 h (Manuscript III). With transcriptomics and proteomics 
technologies we noticed differential expression of numerous transcripts and proteins 
involved in lipogenesis, lipid transport and hepatocellular injury. In the transcript levels, we 
identified significant down-regulation of PXR, CAR and HNF4α as well as its target drug 
metabolizing enzymes CYP1A2, 2B6, 2C8, 2C9,2C19 and 3A4, phase 2 DMEs including 
UGT1A6 and 2B7, SULT2A1 and 1E1. In the protein level, lower trends of cytochrome 
P450 were observed, however the difference was not statistically significant. The 
variability associated with the increasing passage number in HepaRG cell line as well as 
the changes involved in the biological processes such protein stabilization, or the relative 
half-life of mRNA in comparison to proteins may have contributed to this variability 
observed. 
In the final part of the dissertation, we adapted the model, developed in HepaRG to 
human hepatocytes where the fat over-load led to 6-fold increase in neutral lipid 
accumulation in hepatocytes showing the characteristics of hepatic steatosis model 
(Manuscript IV). In addition, 40 proteins showed a significant change in human 
hepatocyte model for steatosis assessed using SWATH-MS. When these proteins were 
screened in human liver tissue with progressive stages of NAFLD we noticed 6 proteins 





We believe this work that is a conjunction of in vitro model NAFLD along with the 
SWATH-MS, DIA based proteomics approach provides vital information for the 
identification of novel biomarkers to predict the early stages of the disease. We believe 
this will help in diagnosis of NAFLD in stages prior to NASH that may aid in more effective 
treatment before the disease had developed to more progressive stages. In addition, we 
believe these proteins may also have the potential as predictive biomarkers in treatment 
and therapy. 
 
 
 
